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ABSTRACT 
BACKGROUND: Palliative chemotherapy is cancer-directed therapy, which aims at stopping or 
slowing down the progression of the malignancy even though it may not have any potential for 
remission or cure. In South Africa, delayed diagnosis of childhood cancer is a common problem 
for a variety of reasons including lack of health care facilities, transport, information about the 
disease and delayed presentation due to traditional healer visits or other cultural issues. In patients 
who present with advanced cancer, or in patients with relapsed cancer without realistic hope of 
cure, palliative chemotherapy can be offered in an attempt to manage symptoms, improve quality 
of life and prolong meaningful survival. 
 
OBJECTIVES: This research study evaluated South African paediatric oncologists’ perspectives 
and practices regarding the use of chemotherapy in patients with cancer with no realistic hope of 
cure. The second part of the study described the use of palliative chemotherapy in patients who 
received treatment at the Steve Biko Academic Hospital Paediatric oncology unit.  
 
DESIGN & METHOD: An online survey was conducted among paediatric oncologists in South 
Africa. The main aims of the questionnaire were to assess paediatric oncologists’ considerations 
around the use of palliative chemotherapy, and then focus on the most recent patients treated with 
palliative chemotherapy. For the second part of the study, a file review was done of deceased 
patients who died in the period from January 2012 to December 2018 and who had received 
palliative chemotherapy as part of their cancer management. We reviewed diagnoses, palliative 
chemotherapy regimens, timing of initiation and stopping palliative chemotherapy, and whether 
end of life decisions and discussions were documented. 
 
RESULTS: A total of 41 participants completed the survey, giving a response rate of 89%. The 
majority of the paediatric oncologists were either neutral or agreed that palliative chemotherapy 
should be considered. The most important treatment aim was to improve quality of life of the 
patient (92.7% of respondents). The most important considerations when prescribing palliative 
chemotherapy was to minimise toxicity of the chemotherapy regimen (4.56 mean, SD=0.5 utilising 
a 5 point scale where 1=not important to 5=very important), and the effectiveness of the 
chemotherapy (4.37; SD=0.48). Only 19.5% of patients received treatment primarily because 
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parents requested it. According to the oncologists polled, the key considerations were largely 
achieved in the most recent patient treated with palliative chemotherapy. Individual opinions and 
preferences concerning recommending palliative chemotherapy differ between paediatric 
oncologists.  
Of the 305 patient deaths recorded in the study period, a total of 74 patients had received palliative 
chemotherapy and were included in the file review. The most common diagnoses were 
neuroblastoma (18.2%), retinoblastoma (15.6%) and osteosarcoma (14.3%). At the time of 
diagnosis, the median age of the patients was 6.0 years (range 0.3 to 17.6 years). In 47 patients 
(63.5%) the disease was deemed incurable at first diagnosis and palliative chemotherapy given 
from the onset of treatment, while 27 patients (36.5%) were given palliative chemotherapy at 
relapse. The median time from last palliative chemotherapy to death was 30 days (range 0-742 
days). The main documented aim of palliative chemotherapy was to improve symptom control 
(97.3%) while parents’ opinion played an important role in 32.9% of cases.  About half of the 
patients (41 of 74, 55.4%) had documentation of symptomatic improvement. 
 
CONCLUSION: Although the overall attitude towards the use of palliative chemotherapy is 
positive, there is great inter-individual variation between oncologists in opinions and experience. 
The lack of empirical data to justify recommendations about palliative chemotherapy remains a 
problem, and the researcher hopes that this study will spark productive discussion and planning 
towards more structured use of palliative chemotherapy in children with cancer in South Africa. 
This study shows that many decisions around end of life care and decision-making could be better 
researched using a quantitative, prospective, interview-based approach. Repeated measurements 
of the child and family’s quality of life and its associations with palliative chemotherapy should 
be a research priority in future. 
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CHAPTER 1: Introduction 
1.1 Background 
Over the last 50 years there has been consistent improvement in survival rates of childhood 
cancer.(1) In high income countries the 5-year survival rates now approach 75%, with rapid 
advances in new areas such as cancer vaccines, immunotherapy and personalised cancer 
treatment.(1) In contrast to first world countries, like the United States (US) where cancer is the 
leading cause of non-accidental deaths in children 1-14y old,(2) South African children are still 
more likely to die of infectious diseases and malnutrition.(3,4) With improved control of infectious 
diseases as well as improved rate of diagnosis, the number of children diagnosed with cancer 
annually in South Africa is expected to increase.(3, 5) 
   
Palliative care is an important research area in paediatric oncology because ultimately, despite all 
the recent advances in treatment, 25 – 30% of all children diagnosed with cancer in high income 
countries will die due to the disease.(6) In Africa the percentage of cancer-related mortality is 
much higher (close to 60%) due to late presentation and advanced disease.(3) Late diagnosis is 
common in Africa, which makes palliative care often the only management option. Reasons for 
late presentation include lack of health care facilities, transport, information about the disease and 
delayed presentation due to traditional healer visits or other cultural issues.(4) Unfortunately there 
are many challenges in the provision of effective palliative care in South Africa, including a lack 
of trained health care professionals who can offer palliative care, as well as cultural beliefs that 
may prevent families from seeking help for their dying child.(5) 
 
1.2 Definition of palliative care 
Palliative care is “an approach that improves the quality of life of patients and their families facing 
the problems associated with life-threatening illness, through the prevention and relief of suffering 
by means of early identification and impeccable assessment and treatment of pain and other 
problems, physical, psychosocial and spiritual.”(7,8) According to the World Health Organisation 
(WHO), palliative care for children is “the active total care of the child’s body, mind and spirit, 
and also involves giving support to the family. Palliative care begins when illness is diagnosed, 
and continues regardless of whether or not a child receives treatment directed at the disease.”(7) It 
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is widely believed that a patient has to be “off chemotherapy” to receive palliative care. However, 
the WHO clearly states that the two modalities (active chemotherapy treatment and palliative care) 
can and should happen simultaneously. It is possible and advisable to initiate palliative care while 
the patient is on disease-directed treatment, and disease-directed treatment in the form of 
chemotherapy may play an important role in the palliative care strategy.  
 
When considering the diagnosis of childhood cancer, the term “life-threatening” which describes 
a disease for which cure is possible but may fail definitely applies. One of the crucial aims of 
paediatric palliative care is to prolong life of reasonable quality, but also to avoid futile treatments 
which may be potentially harmful.(8)  
 
1.3 Palliative chemotherapy 
Palliative chemotherapy is cancer-directed therapy which aims at stopping or slowing down the 
progression of the malignancy even though it may not have any potential for remission or cure.(9) 
Palliative chemotherapy, in broad terms, refers to the use of cytotoxic chemotherapy (oral or 
intravenous) for treatment of a patient without a realistic chance of cure. The focus at this stage is 
symptom control (reduction of common symptoms such as bleeding, dyspnoea and pain) and 
prolongation of life, as well as improvement of quality of life.(10) Although the disease is deemed 
incurable, some degree of disease control and improvement also adds symptomatic control. In a 
sense the use of palliative chemotherapy can be seen as a midway between all or nothing – 
continuing some cancer-directed therapy with the knowledge that it is unlikely to be curative, while 
focusing on symptom control, quality of life and minimising side-effects.(1)  
 
1.4 Metronomic chemotherapy 
The word “metronomic” is derived from the word “metronome” which refers to a musical device 
that produces regular clicks. Metronomic chemotherapy is defined as “the chronic administration 
of chemotherapeutic agents at relatively low, minimally toxic doses, and with no prolonged drug-
free breaks.”(11–15) This produces a sustained low blood level of the chemotherapy drug without 
any major side effects. The target of metronomic chemotherapy is inhibition of tumour growth 
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through anti-angiogenic mechanisms, compared to conventional chemotherapy that treats cancer 
directly by killing rapidly dividing tumour cells.(11)  
 
A wide range of conventional chemotherapy drugs including cyclophosphamide, methotrexate, 
etoposide and vinblastine have been shown to be cytotoxic to circulating endothelial cells. These 
endothelial cells are inherently less likely to develop drug resistance. For this reason significant 
inhibition of tumour growth can sometimes be achieved with metronomic (low dose, prolonged) 
chemotherapy even in tumours that are resistant to maximum tolerated doses of conventional 
chemotherapy.(11) Other drugs that are commonly used in addition to the above-mentioned 
chemotherapy drugs as part of a metronomic regimen includes celecoxib, thalidomide, retinoic 
acid, cholecalciferol, fenofibrate and temozolamide. These are known drugs not initially developed 
as anticancer agents that are “repositioned” to treat new indications, specifically targeting the 
tumour microenvironment (including stimulating an antitumour immune response, targeting 
cancer cells and targeting the tumour vasculature).     
 
The use of metronomic chemotherapy is mostly described in the context of multiple relapsed or 
refractory cancer. It certainly is a very effective form of palliative chemotherapy but it could and 
likely will be used in the future with curative intent. It has already been used as part of curative 
strategy for high risk rhabdomyosarcoma.(16)  So while it is not restricted to the palliative 
paradigm that remains the major focus of its use to date. There is a good deal of utility in using 
low toxicity chemotherapy strategies for palliation in the setting of relapsed and refractory 
malignancy. Bahl(11) described this clearly when stating “at this crucial junction of progressive 
disease and limited options of chemotherapy, declining further treatment for the patient usually 
gives the patient and their caretakers a feeling of being abandoned. Saying yes to an alternate way 
of administering chemotherapy drugs may prevent impending doom and provides a ray of hope.”  
 
1.5 Possible indications for palliative chemotherapy 
Patients who present with advanced incurable cancer or patients who are refractory to conventional 
therapy will arrive at a point where they no longer have a reasonable chance of cure. At this stage 
the treating team and the parents will have to consider different options of treatment,  such as 
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palliative care with symptom relief only, further aggressive treatments (with good symptom 
control included), or the “in between” option of palliative chemotherapy.(17) This is often one of 
the most difficult decisions facing parents and physicians in the management of a child with cancer. 
 
It is not easy to find the balance between “cure at all costs” and deciding when to direct the focus 
of treatment towards symptom control, minimising suffering and maximising quality of life.(1) 
The philosophy of palliative care supports the belief that for some children the relief of suffering 
may be a more appropriate and more attainable goal than “cure at all costs”.  
 
Research has been done on the factors that affect treatment choices in paediatric palliative 
care.(1,2,9,17–19). From the perspective of parents, the important factors considered in making 
the decision between aggressive therapy and supportive care alone were found to be hope, 
increased survival time and the child’s quality of life.(17) For health care professionals, the child’s 
quality of life and increased survival time were the most important factors, with financial 
considerations also included.(17).  
 
In these very important decisions it is suggested that health care professionals explicitly address 
the issues of hope, quality of life and survival during discussions with the family and patient.(17) 
Honest communication about what palliative chemotherapy can and cannot offer to the patient 
should facilitate informed decision-making in the interest of the child. It is very important that the 
parents understand the prognosis, as inaccurate perceptions can sometimes lead parents to make 
decisions to continue aggressive therapy with unrealistic expectations and false hope.(18) When 
families choose to go ahead with palliative chemotherapy in an attempt to prolong life, they should 
have an understanding of the expected trajectory of the illness.(20)  
 
Measuring the efficacy of palliative chemotherapy would depend greatly on the patient and 
family’s treatment goals. Some families may want to fight for a cure regardless of the odds, while 
other families may focus purely on quality of life. The duty of the health care provider is to help 
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1.6 Benefits and potential problems associated with palliative chemotherapy 
Palliative chemotherapy aims at stopping or slowing down the progression of the malignancy in 
order to improve or maintain the quality of life of children with incurable cancer. It often improves 
symptom control by controlling the underlying disease process. Palliative chemotherapy has fewer 
side-effects than aggressive chemotherapy and can often be administered on an outpatient basis, 
avoiding the need for prolonged hospital stay. One very important potential benefit of using 
palliative chemotherapy could be buying time for the patient and family to do the work of dying – 
having important conversations, coming to terms with the fact that the condition is incurable, 
achieving personal goals, working on a legacy, and doing anticipatory grief work.(8)   
 
Families should be informed about the potential problems associated with palliative chemotherapy. 
Patients receiving palliative chemotherapy are at risk of spending precious time in hospital away 
from their families, receiving treatment with no or minimal benefit, being exposed to unnecessary 
painful procedures, experiencing unwanted side-effects, entertaining false hope of extended life 
(unrealistic expectations), and therefore not preparing for death and missing out on appropriate 
palliative care.(10,18) Patients may also die prematurely from sepsis or bleeding as a result of 
chemotherapy related complications. The financial burden to the family when including travelling 
costs, time away from work for caregivers and loss of income as a result of giving palliative 
chemotherapy, also need to be taken into account. It is important to make the purpose of the 
palliative chemotherapy clear to parents, and also to help them understand that it is reasonable to 




Efficient palliative care is one of the cornerstones of cancer treatment. There are different reasons 
why cancer in children may be advanced and even incurable at presentation to an oncology unit. 
Childhood cancer is very rare and early subtle signs may be difficult to recognise on first 
presentation to a health service.  There may be no option for cure, or attempts at cure may not be 
successful and the disease may relapse or progress. In these situations, palliative chemotherapy 
may be offered in an attempt to improve quality of life and prolong survival. 
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This introductory chapter provided background on the importance of palliative care research in 
paediatric oncology, the concept of palliative chemotherapy and its possible benefits as well as 
potential problems. The need for awareness around palliative chemotherapy and the usage thereof 
has been introduced and its merits documented. The next chapter reviews local and international 
literature pertaining to health care professionals as well as patients and parents’ opinion on the use 
of palliative chemotherapy, treatment decisions around the end of life, the differences in palliative 
chemotherapy in children compared to adults, and the differences between palliative chemotherapy 
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CHAPTER 2: Literature review 
2.1 Overview 
Chapter 2 presents the findings of a literature search on the use of palliative chemotherapy and 
treatment decisions around the end of life. There are many articles describing the goals and 
preferences of children who suffer from cancer and their parents when the disease trajectory moves 
to a point where the prognosis becomes poor. For some of these families, palliative care 
(management of symptoms with the focus on quality of life) takes preference, whereas other 
families will pursue cure at all costs even if it may mean that the child receives disease-directed 
treatment way beyond what is clinically advisable or even acceptable. Palliative chemotherapy is 
seen by some as a good compromise between these two extremes, providing symptom relief and 
improvement in quality of life whilst at the same time offering some disease-directed treatment. 
The literature findings of the general benefits of and problems with palliative chemotherapy, the 
opinion of health care professionals and caregivers, the role of the young patient’s opinion in 
palliative decision-making and the differences between paediatric and adult palliative 
chemotherapy are discussed  and an attempt made to emphasise the differences between high 
income countries and our context of a low-resource setting.  
 
2.2 Literature search methodology 
A literature search was done to explore the subject.  The search was limited to published works in 
the English language after the year 2000.  A Boolean search was done through Google Scholar, 
Medline and Pubmed using the keywords “palliative chemotherapy”, “palliative care in oncology”, 
“end of life care”, cross-linked with “paediatrics” or “children”. A separate search was conducted 
to identify articles on the oncologists’ use of palliative chemotherapy. This search was done using 
key words “oncologist”, “palliative chemotherapy”, “decisions”.  
Key researchers in the field were identified by amount of relevant publications and all their 
previous publications were searched to find relevant articles. 
References quoted by the two most relevant articles found were also searched to find more articles 
that are relevant. 
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2.3 The role of palliative chemotherapy at the end of life 
Waldman and Wolfe(21) wrote a review article on palliative care for children with cancer in 2013, 
where they mention a few of the issues around palliative chemotherapy. They question the 
definition of palliative chemotherapy, quoted as “chemotherapy that is administered without intent 
to cure, for the purpose of alleviating symptoms and/or extending life”, asking specifically at what 
point chemotherapy should be labelled to be palliative as opposed to chemotherapy given for the 
aim of cure. They also mention a paucity of data on the use of palliative chemotherapy in children. 
The difficulty of balancing the toxicities of cancer-directed therapy with the effect it has on the 
quality of life becomes increasingly difficult as the prognosis worsens with subsequent recurrences 
of disease. Towards the end of life, increased survival and quality of life often becomes two 
opposing goals, with toxic chemotherapy given in an (often futile) attempt to increase survival 
leading to rapidly worsening of quality of life. 
 
Administering chemotherapy in the last 30 days of life in patients with poor prognosis, with 
palliative intent, has been used as a marker for “aggressiveness of cancer care” as well as an 
indicator of quality care near the end of life.(22) In multiple articles from adult oncology settings 
it has been shown that treatment near death is becoming increasingly aggressive,(23,24) clinicians 
consistently tend to overestimate survival,(25) and that the use of palliative care in conjunction 
with disease-directed chemotherapy nearing the end of life reduces the use of futile anticancer 
chemotherapy in the last 30 days of life.(22,24,26) These articles report that between 9 and 43% 
of patients received chemotherapy in the last 30 days of life. 
 
Wolfe et al(27) looked at the symptoms and suffering at the end of life in children with cancer in 
the US. Out of 103 children whose parents were interviewed after their child’s death, 56% reported 
that their child received cancer-directed treatment in the last month of life. These children had 
received an average of 3.7 different regimens of cancer-directed treatment and 23% of them were 
enrolled in a phase I trial. A total of 49% of them died in hospital, and half of these in-hospital 
deaths happened in the intensive care unit. This study emphasises again that when long-term 
survival chances are low, cancer-directed therapy (in other words palliative chemotherapy) should 
not be offered without concurrent attention to palliative care principles. 
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Browner et al wrote in a 2005 review article on chemotherapy(28) that the treatment modalities 
for advanced cancer may include palliative (hospice) care, palliative chemotherapy as well as 
phase I trials. The article discusses the importance of allowing palliative care from the time of 
diagnosis, having a continuum of care starting from aggressive care and moving on to comfort 
care, and allowing these aspects of care to happen simultaneously.  
 
2.4 When “palliative” chemotherapy gets in the way of good palliative care 
A recurrent concern in the literature is summarised by Randén(10) in a 2013 article discussing 
treatment decisions and discontinuation of palliative chemotherapy near the end of life, namely 
that giving chemotherapy (disease-directed, even though the aim may be palliative) may lead to 
false hopes that life will be prolonged. The big concern in this situation is that the patient’s 
opportunities to do the “work of dying” and prepare for death may be hampered. In the same way, 
the disease-directed treatment may prevent or delay access to good palliative care.  
 
In 2014, Harrington(26) also published a discussion on the difficult issues around chemotherapy 
at the end of life. This discussion (using an adult patient case as an example) stressed the 
importance of defining clear and appropriate goals of chemotherapy use, and of distinguishing 
curative from palliative chemotherapy in discussion with patients and families. This article also 
states that for oncologists, giving third or fourth line chemotherapy may be an easier option than 
having the difficult discussion about hospice care. This uncertainty about goals of treatment may 
cause the family and the patient to be unprepared for what the final weeks may bring. 
 
Chan et al (2016),(29) adds the following to the list of potential problems with palliative 
chemotherapy. Firstly, the toxicity of chemotherapy may lead to prolonged hospitalisation for 
various possible reasons including nausea, vomiting and diarrhoea, bone marrow suppression, 
febrile neutropaenia and septicaemia. All these complications will impair quality of life (QOL) 
significantly and may even shorten survival. Secondly, these patients may delay entering hospice 
care. In many countries hospice requires a do not resuscitate (DNR) order to be in place, which 
may be difficult to accept for patients still on active disease-directed treatment. Another potential 
issue is the cost of palliative chemotherapy, which includes also the costs of supportive care needed 
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when receiving chemotherapy (laboratory tests, imaging, blood products, clinic and hospital 
visits). A great concern raised in this article agrees with the one of Harrington(26) (see above) that 
in clinics where physicians work under pressure and time is precious, it may be easier just to 
prescribe chemotherapy rather than to spend the hours required to break bad news to a patient or 
family and come up with an acceptable palliative care plan (which may or may not include 
chemotherapy). The importance of effective communication is stressed repeatedly in this and many 
other articles.    
 
2.5 Health care professionals’ opinion on palliative chemotherapy  
In 1998, the American Society of Clinical Oncology did a survey on the attitudes and practices 
among paediatric oncologists regarding end-of-life care. This survey was published by Hilden et 
al(30) and included questions on training in palliative care, current practice in end-of-life care, 
barriers to the delivery of end-of-life care, decision making and individual experiences with 
terminal patients. The questionnaire was completed by 228 oncologists. This survey did not 
specifically address palliative chemotherapy but provided important information on areas that need 
improvement in end-of-life care delivery, including the need for specific and formal education in 
paediatric palliative care, the need for a multidisciplinary approach to the care of the dying child 
and the need for thorough communication with patients, and the ability to initiate a discussion on 
advance directives and end-of-life care. 
 
The need to be able to acknowledge impending death was identified as an important issue, and 
discussions around this in the survey indicated that oncologists often recommend continued active 
treatment (chemotherapy) for patients who have had multiple relapses. The importance of offering 
concurrent palliative care with the active treatment is stressed in the summary of these survey 
findings. 
 
Behl et al(31) reported in 2010 on a semi qualitative survey done on adult oncologists, asking the 
question “What do oncologists say about chemotherapy at the very end of life?” The survey was 
completed by 61 oncologists, and concluded that it is a very complex question in which oncologists 
should be collaborating with palliative care providers. Knowing that this survey was done with 
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oncologists treating adult patients, the themes may be somewhat different as what will be expected 
from paediatric oncologists. However, important issues that were identified included:  
 Decisions on chemotherapy at the end of life are often patient (or family) driven 
 Even a small chance of benefit for the patient may justify the use of chemotherapy at the 
end of life 
 The practice of using chemotherapy at the end of life may be detrimental as it often prevents 
or delays the initiation of hospice services 
 These decisions are complicated and revolve around society values, the oncologist alone 
cannot claim responsibility 
 There are many barriers to end-of-life discussions. 
 
A study done by Wusthoff et al in 2005(19) used two identical case histories in interviews with 48 
paediatric oncologists working in San Francisco in the US to look at differences in estimates of 
curability and treatment recommendations. Both case histories were of patients with advanced 
cancer, and the literature including prognostic data, were included. The results demonstrated a 
large variability in treatment goals, perceived chances for cure as well as the degree to which 
further curative intervention would be considered desirable for each patient. Physicians and 
families are influenced by their own values when considering treatment goals, this may to some 
extent explain the wide variation found in this study. However, the study recommends that “the 
duty of the physician is to help the patient and family achieve the goals that are most closely 
aligned with the family’s own values.” The importance of recognising their own bias in 
communication, discussing difficult cases with colleagues and offering a second opinion is clear 
in these very difficult advanced cancer patients. 
 
Kang et al(2) did an email survey on 422 paediatric oncologists practicing in the US in 2010. This 
survey described the oncologists’ general treatment considerations when prescribing palliative 
chemotherapy, and also asked some questions about treatment considerations around their most 
recent patient treated with palliative chemotherapy. In general, this survey revealed that the three 
most common considerations when prescribing palliative chemotherapy were toxicity, family 
preference and potential to relieve symptoms. However, when looking at the most recent patient 
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treated, a worrying finding was that their aims were often not achieved, and that 40.8% of 
oncologists reported prescribing the palliative chemotherapy mainly for parental wishes. Another 
important finding in this study is that most oncologists (87.5%) felt that their preferences around 
the use of palliative chemotherapy often differed from those of their colleagues. 
 
No matter what the opinion of the treating oncologist is, it will have a great impact on the eventual 
decision of the family whether to consider palliative chemotherapy for their child with incurable 
cancer. 
 
2.6 Parents’ opinions on palliative chemotherapy 
For families, the choice between palliative chemotherapy and supportive care alone may be one of 
the most difficult decisions in the childhood cancer journey.(9,18,32,33) Understanding the issues 
surrounding this choice is a difficult topic to study and is better approached in qualitative 
interview-based studies. Quite a few such studies looked at parents’ approaches to treatment when 
standard therapy has failed to cure their child’s cancer. This literature review will attempt to 
summarise the important findings in a selection of the more recent publications.   
 
Mack et al(18) did a retrospective survey in 2008 among a group of bereaved parents.  Of the 141 
parents included, 53 (38%) had children who died after receiving cancer-directed therapy for 
palliation (in a situation where cure was no longer possible). Parents were asked whether they 
perceived any benefit or suffering related to the treatment given after recognising that cure was no 
longer realistic. The majority of these parents felt that their child had experienced some suffering 
from the therapy with little or no benefit. More importantly, many of these families would not 
recommend treatment for incurable cancer to other families even if they had chosen treatment for 
their own child.(18) An important limitation in this study was the quantitative nature of the 
questionnaire. It was a vignette-based questionnaire and did not have open-ended questions. In 
these types of situations so much of the individual patient and family situation, and even the 
similarity to the vignette, may influence the parents’ answers. This type of study design cannot 
assess and sufficiently comment on those complicated personal issues surrounding the eventual 
choices and opinions that parents report as a yes/no answer on a questionnaire. 
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Another study done in Germany by Hechler et al(34) in 2008 with a group of bereaved parents 
used a semi-structured interview to discuss distressing symptoms and quality of life in their 
children during the end-of-life period. A total of 48 parents were interviewed. Thirty-six patients 
(75%) died of progression of disease, and of this group, 50% received cancer-directed therapy at 
the end of life. Twenty-three of the children (48%) died at home and the remainder in hospital. Of 
the 18 patients who received cancer-directed therapy, only four children clearly benefited from the 
therapy according to their parents. The majority of these children suffered from several side effects 
related to the therapy, and most parents rated the therapy not as effective but as troublesome for 
their children.  
 
Using a different semi-structured interview approach, Bluebond-Langner et al(9) did a prospective 
study of parents in 2010 whose children had disease that recurred and had a less than 30% chance 
of cure. Important findings in this study were that parents viewed cancer-directed and symptom-
directed treatment as a continuum of care, not as mutually exclusive approaches, and that parents 
will discuss and negotiate care rather than being constrained by what the oncologist offers. A total 
of 34 children were enrolled and their courses of treatment, including treatment decisions by their 
parents, were prospectively studied. In 28 of the 34 patients (82.4%), parents chose to continue 
with cancer-directed therapy. This included phase I/II trials, second-line (palliative) chemotherapy, 
newer interventions (metronomic type therapy including anti-angiogenesis drugs) or more 
aggressive therapies (high-dose chemotherapy with stem cell rescue). Of the 25 children who died 
during the study period, 11 children (44%) received some cancer-directed therapy in the last month 
of life. One important finding in this study, in contrast to the study by Mack et al(18), was that 
parents valued more time with their children, and were not regretting making choices that included 
giving palliative chemotherapy. A strong palliative care presence in Bluebond-Langner’s 
institution could explain this difference. 
 
Another interview-based prospective study by Tomlinson et al(32) in 2011  included 77 parents of 
children who had been diagnosed with terminal cancer, but who were not yet at the point of 
decision-making regarding end of life care plans. This study primarily looked at the differences 
between parents’ and health care professionals’ opinion on palliative chemotherapy versus 
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supportive care alone. The findings were impressive – significantly more parents (42/77, 54.5%) 
than health care professionals (20/128, 15.6%) were in favour of palliative chemotherapy. 
Although they reported similar considerations during decision-making in the two groups, hope was 
a much more important factor for parents. In fact, parents reported that hope for a cure was so great 
that they may choose chemotherapy even it reduced the child’s QOL and survival time.   
 
It is clear from these studies that decision making around palliative chemotherapy for their children 
is a complicated situation for parents, with many different contributing factors. It is interesting that 
the prospective studies(9,32) (with parents whose children were still alive at the start of the study) 
reported a much more positive attitude towards palliative chemotherapy, whilst a lot of the 
bereaved parents(18,34) felt that they should not have agreed to chemotherapy.  
 
As a final statement, it is the opinion of the researcher that one of the most important caveats with 
palliative chemotherapy is that it must not prevent the parents from doing the emotional 
preparation for the death of their child. Parents’ expectations of palliative chemotherapy need to 
be carefully and continually guided towards the goals of symptom control, improvement in QOL, 
and “buying extra time” for the patient and family to do the “work of dying”.(35)   
 
2.7 The role of the sick child in end of life care decision making 
Older children and adolescents frequently prefer to be included in end of life discussions.(8) Even 
younger children, especially when they have been exposed to an oncology ward or setting for a 
prolonged period, may express their desire to be involved in hearing what the doctors discuss with 
their parents. Most health care professionals agree that children should be informed about their 
prognosis, as well as changes in the treatment plan and disease trajectory.(36) This type of 
disclosure will facilitate communication between the child and parents, and will most likely 
improve the family’s experience of the end of life journey.  
 
Matsuyama et al(37) published a review in 2006 of studies done on adult patients who chose 
palliative chemotherapy. In this review, multiple studies showed that adult patients are willing to 
undergo treatment for smaller benefit than their health providers, and for a small chance of 
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survival. No similar studies have been done in children and will be almost impossible to do. 
However, the stark contrast between bereaved parents’ opinions in Mack et al(18) and adult 
patients’ opinions in Matsuyama et al(37) creates the question of what paediatric patients would 
choose for themselves if they were allowed to choose. 
 
In contrast with the impressive amount of studies focusing on clinicians and parents’ preferences 
around end of life care and palliative chemotherapy, there are very few articles looking primarily 
at the opinion of the child at the end of life. Hinds et al(38) published a study in 2006 in which 
they interviewed 20 children with cancer between the ages of 10 and 20 and asked specific 
questions about their care and decision making. These children all had terminal cancer and had 
been part of an end-of-life discussion in the week preceding the interview. What they found was 
that these children understood the nature of the discussion, the eventual consequences of their 
decisions, and that they were able to participate in this very complex multi-faceted decision-
making process. As a conclusion, the study supported the ability of children between 10 and 20 
years old to take active part in the end-of-life decision-making process. A 2016 narrative 
systematic review by Bluebond-Langner et al(39) looked at defining the role of adolescents, 
parents and healthcare professionals in the decision-making process. They found a large inter-
individual variation concerning preferences for information. However, importantly, none of the 
studies indicated preference for a high degree of independence in decision-making and in fact 
urging parents and adolescents towards independent decision-making may add to distress and 
confusion. 
  
In a poignant article “Caring for the child with cancer at the close of life”, Hurwitz et al(40) tell 
the story of a patient with terminal leukaemia (at second relapse) and describes the process of the 
child’s involvement in end of life decision making. A few important comments and suggestions 
are made in this article to assist the clinician with this difficult situation. Asking the parents their 
preference for communicating prognostic information to their child will build trust between the 
parents and the medical team. The importance of being truthful when asked direct questions is 
emphasised. They also highlight the process of following prognostic disclosure with a discussion 
on goals of care. 
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Perhaps the most relevant comment for this literature review is that most parents and families 
desire to continue disease-directed treatment together with symptomatic care directed at improving 
QOL – “concurrent care”(40).  
 
2.8 How does palliative chemotherapy differ in low-resource settings? 
All the studies discussed up to this point in the literature review were set in high income countries 
where many of the patients present and are diagnosed early and have multiple treatment options 
available, which include standard chemotherapy, biological, and targeted therapy, clinical trials 
with the latest new chemotherapy and other drugs, as well as access to stem cell transplant. It is 
not unusual for most children to go through two or three chemotherapy regimens before being 
viewed as possibly not curable.(27) At this stage some clinicians continue to give more intense or 
experimental therapy without having the important discussions needed when the disease trajectory 
changes. This lack of prognostic disclosure may be as a result of reluctance of the clinician to 
engage with the family on such a deep level – thus it may be easier to just continue to a further 
(possibly desperate) treatment regimen.(10,26) 
 
In an editorial piece in Acta Paediatrica 2016, Nicolas Andre(41) clarifies the connection between 
metronomic chemotherapy and palliative chemotherapy when he explains that the combination of 
disease control – even in metastatic or refractory tumours – with low levels of toxicity, makes 
metronomic chemotherapy ideal to use in a palliative setting. As an example the researcher 
reviewed the SIOP-PODC treatment guidelines for neuroblastoma in low- and middle-income 
(LMIC) settings.(42) It is recognised that many LMIC struggle with resources, cost of drugs, lack 
of access to monoclonal antibodies and biological treatments, and lack of access to bone marrow 
transplant. Knowing that advanced (high-risk) neuroblastoma needs very intense treatment with 
many of these modalities that are not accessible in LMIC, patients may be prescribed palliative 
care from the time of diagnosis. 
 
A group of children from Mali, a LMIC in the North Western part of Africa, was treated with 
metronomic chemotherapy with palliative intent.(15) Half of the group (6/12) were treated with 
palliative intent using a metronomic regimen from the time of diagnosis, while the other half had 
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progressive disease on curative treatment. In other words, 50% of the patients included in this 
study did not previously receive any treatment with curative intent due to the advanced state of 
disease at diagnosis. Their diagnoses included stage IV neuroblastoma, bilateral retinoblastoma, 
trilateral retinoblastoma and bilateral nephroblastoma. The metronomic treatment was well 




The articles summarised in this literature review illustrate some of the more important issues 
around the use of palliative chemotherapy. For the purpose of the proposed survey, the opinions 
of health care professionals on the use of palliative chemotherapy were discussed in some detail 
with focus on the aims and perceived success thereof in treating children with incurable cancer. 
The paucity of data from LMIC was striking, with very few publications to be found.(15) By 
summarising the use of palliative chemotherapy in South Africa, and including some statistics 
from a single oncology unit, the hope is that a common ground will be established that can be used 
to move forward in the care for these patients in South Africa.  
 
2.10 Rationale for the study 
Despite advances in curing childhood cancer, some children will die from recurrent or incurable 
disease. When cure becomes unlikely, patients and health care professionals have to decide 
whether to offer further aggressive chemotherapy, to consider palliative chemotherapy or to offer 
supportive care only. 
 
Palliative chemotherapy is given with the intent to improve quality of life in a patient with 
incurable cancer. Many factors may influence whether the use of palliative chemotherapy will be 
of benefit to the child. Within a family living in extreme poverty, the use of money to fund transport 
to hospital to get access to palliative chemotherapy may mean that there will be no money left for 
food or other basic needs.  
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Until now, no research has been published on the use of palliative or metronomic chemotherapy 
in Southern Africa. With many patients presenting late, with either incurable of very advanced 
cancer, the use of palliative chemotherapy may be important to improve quality of life and manage 
difficult symptoms in the end of life period. This study includes a birds-eye view of oncologists’ 
opinions from all over South Africa, as well as zooming into the detail of what is happening in one 
unit with the overarching aim of giving a comprehensive and detailed snapshot of palliative 
chemotherapy in children with cancer in South Africa. 
 
2.11 Aims and objectives 
2.11.1 Part 1: Survey 
Aim: To describe paediatric oncologists in South Africa’s perspectives and practices regarding 
palliative chemotherapy 
Objectives:  
 To describe paediatric oncologists’ treatment considerations regarding the general use 
of palliative chemotherapy. 
 To assess treatment considerations that influenced paediatric oncologists’ therapy 
recommendations for their most recent patient receiving palliative chemotherapy. 
 
2.11.2 Part 2: File review 
Aim: To investigate the use of chemotherapy at the end of life in patients treated at the paediatric 
oncology unit of Steve Biko Academic Hospital in Pretoria. 
Objectives: 
 To review the clinical course of patients who died during/after receiving treatment in 
the Steve Biko Academic Hospital paediatric oncology unit. 
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CHAPTER 3: Methodology 
3.1 Methodology part 1: Survey 
3.1.1 Study Design 
Part one of the study was a cross-sectional quantitative survey.  
 
3.1.2 Study Site 
A link to the survey was sent out to all paediatric oncologists currently working with oncology 
patients in South Africa. 
 
3.1.3 Study Population 
All paediatric oncologists, fellows in paediatric oncology and medical officers working in 
paediatric oncology units on a permanent basis in all the provinces of South Africa were invited 
to take part. 
 
3.1.4 Selection Criteria 
 Inclusion criteria: All paediatric oncologists, fellows in paediatric oncology and medical 
officers working in paediatric oncology units on a permanent basis in all the provinces of 
South Africa were allowed to take part. 
 Exclusion criteria: Fellows and medical officers who have just begun working in 
oncology (fewer than six months of time spent in the oncology service) were excluded, as 
well as paediatric registrars rotating in oncology service. 
 
3.1.5 Sample size 
There are 46 doctors working with paediatric oncology patients on a full time basis in South Africa. 
The aim was to get at least an 80% response rate (37 doctors).  
 
3.1.6 Sampling method 
An email link to the questionnaire was sent to all the doctors currently on the South African 
Children’s Cancer Study Group (SACCSG) mailing list. The SACCSG is a group of all the 
paediatric oncologists in the country, and is the central body that co-ordinates all collaborative 
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research done on oncology patients in South Africa. All qualified oncologists, as well as 
haematologists working with paediatric oncology patients and fellows in paediatric oncology are 
members of this group. Members of the group were encouraged to forward the link to the 
questionnaire to any qualified doctors working with them full time in their units who may not yet 
be part of the SACCSG. The method used was convenience sampling; participants who were 
available and willing to take part were included. Although this sampling method is prone to 
significant volunteer bias, the very high response rate we managed to get makes our sample 
representative of the current group of paediatric oncologists in South Africa. 
 
3.1.7 Data Collection Tool 
Data collection tool: Web-based survey (see appendix 1). This survey was developed by a group 
of researchers at The Children’s Hospital of Philadelphia in Pennsylvania, United States of 
America,(2) and their findings published in Pediatric Blood & Cancer journal in September 2012. 
We obtained written permission to use their survey and adapt it for our circumstances as necessary. 
Survey Monkey® (a commercially available tool for online surveys) was used to construct the 
online survey. 
 
3.1.8 Data Collection Method 
Emails were sent to all the SACCSG members and they had permission to forward it to any 
qualified doctors working full time in their units who were not on the mailing list. The email 
contained an introduction letter, explaining the purpose of the study as well as an explanation that 
the study will be anonymous and voluntarily and participation in the survey will be construed as 
providing consent.  
Those interested had to follow a direct link taking them to the online questionnaire.  All data were 
captured anonymously but doctors were asked demographic details such as gender, age category, 
years in practice and current workplace. 
 
3.1.9 Data Storage and Confidentiality 
E-mail addresses were stored on a password-protected private computer. Responses were captured 
anonymously and even though this is a small population, the results did not link the unit or province 
from where a reply came to any of the findings. Study data were password protected. 
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3.2 Methodology Part 2: File Review 
 
3.2.1 Study Design 
The second part of the study was a retrospective descriptive audit of patient files in a single centre. 
 
3.2.2 Study Site 
The audit was done on files of patients seen in the paediatric oncology unit at the Steve Biko 
Academic Hospital. The hospital is a tertiary academic hospital situated in Pretoria, South Africa. 
The oncology unit offers treatment to all patients from Northern Gauteng and Mpumalanga, as 
well as some patients from Limpopo province, and the neighbouring countries Zimbabwe and 
Mozambique (this depends on referral route). The unit sees an average of 110 new oncology and 
haematology patients per year. The unit comprises of a 10 bed day ward for administration of 
outpatient chemotherapy and blood products, as well as an inpatient ward with 30 beds. The 30 
beds include five isolation rooms with two of these equipped for stem cell transplant.       
 
3.2.3 Study Population: 
This included patient files of all patients who died during or after treatment in the paediatric 
oncology unit, Steve Biko Academic Hospital. Folders of all the patients who died in the period 
from January 2012 to December 2018 were reviewed.  
 
3.2.4 Selection Criteria 
Folders of all the patients who died in the period from January 2012 to December 2018 were 
reviewed.  
 Inclusion criteria: All paediatric oncology patients who died from incurable or relapsed 
disease and received palliative chemotherapy. 
 Exclusion criteria: Patients who died during active treatment with curative intent, and 
patients diagnosed with benign haematological diseases (Fanconi anaemia, severe aplastic 
anaemia). All patients who died from incurable or relapsed disease and did not receive 
palliative chemotherapy. 
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3.2.5 Sampling method 
Patient Files: The oncology unit has a list of all the patients managed by the unit who demised. 
This list was used to access the files for the patients on the list who died in the specified period 
(January 2012 to December 2018). Access to files was not a problem as all patient files are kept in 
a secure locked up file cabinet in the unit. This selection of files was scanned and all those who 
died while on active curative treatment were excluded. The remainder of the files were reviewed, 
and those patients who received palliative chemotherapy as part of their treatment were included 
in the final audit. Figure 1 explains the sampling process with the numbers of patient files in each 
category. A total of 74 patient files were included in the final sample. 
 
 
Figure 1: Diagram of sampling process 
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3.2.6 Data Collection: 
A data extraction tool was developed for the file audit (see appendix 3). This audit tool was 
developed based on the literature review taking into account factors that may play a role in the use 
of palliative chemotherapy. The data extraction tool includes the following topics: 
a. Patient information including age, gender and diagnosis 
b. Family structure  
c. Stage of illness at diagnosis and stage when palliative chemotherapy was started 
d. Documentation around palliative chemotherapy (decision and family discussion) 
e. Aims of palliative chemotherapy 
f. Regimen of palliative chemotherapy used (drugs, doses, route) 
g. Cause and location of death 
 
 
3.2.7 Data Storage and Confidentiality 
Medical information was recorded from the files onto the data extraction spreadsheet and each file 
was allocated a study number. To maintain confidentiality, a separate log was kept for linking 
names and study numbers. All data was gathered from files directly onto an electronic spreadsheet 
to reduce the risk of data capture errors. All information is kept on a password protected laptop 
and backed up per institutional policy, which states all work is backed up weekly, to a secure 
server.  
 
3.3 Data Analysis 
3.3.1 Part 1: Questionnaire 
Primary data analysis was done using Survey monkey’s software.  Descriptive statistics were 
calculated for physician and ‘‘most recent patient’’ characteristics. Differences in how individual 
respondents rank generic treatment considerations and how they rank the same considerations for 
their most recent patient were assessed. 
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3.3.2 Part 2: File Audit  
The data from the data capture sheet was inserted into Excel, and descriptive statistics such as 
mean averages, median and proportions used to describe the data. Survival analysis was performed 
using the Kaplan-Meier method. 
 
3.4 Ethical Considerations: 
This study was researcher-funded and undertaken to fulfil requirements for the UCT Masters of 
Philosophy in Palliative Medicine. The research proposal was approved by the UCT HREC on 
24/10/2017, reference 729/2017 (see appendix 4). On request the proposal was also then submitted 
to the UP HREC and approved on 07/11/2018, with reference number 571/2018 (appendix 5). 
 
With regards to the survey, consent was explained in the document accompanying the 
questionnaire and then implied through completion of the survey. Medical doctors working in 
oncology are exposed to these difficult situations and decisions around palliative care on a 
continuous basis. The questionnaire required the respondents to answer questions relating to their 
patients treated with PC. The introduction to the survey included information to prepare 
respondents for these possibly emotionally taxing questions (appendix 2). 
  
Permission to conduct the file audit was granted by the Gauteng Department of Health and Steve 
Biko Academic Hospital (appendix 6). There was minimal risk to patients due to this being a 
retrospective audit of files with no direct involvement of patients.  
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CHAPTER 4: Results of survey 
4.1 Introduction 
Chapter 4 presents the results of the 41 participants’ answers that were collected from 01/10/2018 
until 13/11/2018. Initial emails were sent to the mailing list of the SACCSG, specifically targeting 
the forty-six paediatric oncologists, fellows, and medical officers working full-time in paediatric 
oncology. Forty-one of those responded, giving a response rate of 89%. 
 
4.2 Demographic data 
Table 1 summarises the demographic characteristics of the 41 paediatric oncologists who 
responded to the survey. 
 
 
Table 1: Demographic characteristics of 41 paediatric oncologists 
CHARACTERISTICS n % 
Gender     
Male 9 22% 
Female 32 78% 
Age   
30 – 39 years 17 41.5% 
40 – 46 years 12 29.3% 
47 – 52 years  5 12.2% 
53 – 58 years 3 7.3% 
59+ years  4 9.8% 
Current practice setting   
Academic hospital  21 51.2% 
Private practice 6 14.6% 
Combined private and academic  14 34.2% 
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Years since fellowship training in paediatric haematology/oncology   
 <5 years  14 34.2% 
6 – 10 years  6 14.6% 
11 – 15 years  6 14.6% 
16 – 20 years  4 9.8% 
More than 20 years 4 9.8% 
Full-time medical officer in paediatric haematology/oncology 1 2.4% 
Busy with fellowship training in paediatric haematology/oncology 6 14.6% 
Time spent on direct patient care   
<20% 0 0 
20 – 50% 5 12.2% 
51 – 75%  7 17.1% 
>75% 29 70.7% 
Time spent on oncology patients   
<20% 0 0 
20 – 50% 5 12.2% 
51 – 75%  7 17.1% 
>75% 29 70.7% 
Approximate number of new cancer diagnoses per year in practice   
0 – 50 14 34.2% 
51 – 100  14 34.2% 
101 – 150  11 26.8% 
>150 2 4.9% 
Number of patient deaths in a year   
0 – 1 deaths 2 4.9% 
2 – 9 deaths 22 53.7% 
10+ deaths 17 41.5% 
Standard protocols for relapsed and refractory patients   
Yes for more than 75% of diagnoses 13 31.7% 
Yes for 50 - 74% of diagnoses 20 48.8% 
Yes for <50% of diagnoses 8 19.5% 
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Access to a paediatric palliative care program   
Yes 23 56.1% 
No 9 21.9% 
Occasionally 9 21.9% 
Type of paediatric palliative care program   
Inpatient consult service 17 41.5% 
Outpatient consult service 3 7.3% 
Local hospice 10 24.4% 
Other 11 26.8% 
 
Survey respondents were mostly female (78%) and just over 70% were in the younger two age 
categories between 30 and 46 years. Almost half of the participants were either busy with training 
or newly qualified as paediatric haematologists/oncologists (48.7%). Most were working 
exclusively in the academic setting (51.2%) or combined academic/private (34.2%) with only 
14.6% working solely in private practice. Most physicians (70.7%) spent more than 75% of their 
time on direct patient care of oncology patients.  
 
New cancer diagnoses per year were more or less equally distributed between the three categories 
0 – 50 (34.2%), 51 – 100 (34.2%) and 101 – 150 (26.8%) with only two respondents reporting 
seeing more than 150 new diagnoses per year. Most physicians (53.7%) had 2 – 9 paediatric 
oncology deaths per year, but 41.5% had more than 10 deaths per year. Just over half of the 
physicians (56%) reported access to a paediatric palliative care program, with an additional 22% 
reporting occasional access. The types of palliative programs included inpatient consult services 
(41.5%), local hospice access (24.4%), outpatient consult services (7.3%) and other, which were 
specified to be oncologist trained in palliative care, access to established palliative care services in 
the area, and all the above. 
 
4.3 General experiences with palliative chemotherapy 
The second part of the survey looked at the participants’ general opinion on palliative 
chemotherapy.  Participants were asked about their main goals when considering palliative 
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chemotherapy, and about the factors that influenced this decision. They were also asked how 
frequently their opinion differed from the opinions of their colleagues when considering palliative 
chemotherapy. 
 
4.3.1 Recommending palliative chemotherapy 
Most of the respondents reported that their individual preference regarding the use of palliative 
chemotherapy often (22.5%) or sometimes (67.5%) differed from that of their colleagues.  
Question 12 asked when palliative chemotherapy should be recommended, mentioning two 
specific cases – a child who has relapsed disease, and a child for which no experimental therapies 
are available. Most physicians were either neutral or agreed that palliative chemotherapy should 
be recommended in both these situations (see figure 2). A total of 10 respondents (24.3%) would 
not recommend palliative chemotherapy for a child with a disease that has relapsed, and 9 
respondents (22%) disagreed that palliative chemotherapy should be considered when there are no 
experimental therapies available.  
 
Question 13 went on to assess the recommendation of palliative chemotherapy when considering 
the probability of death from the disease. Five percentage probabilities were given as options, and 
respondents had to say in which of these situations they would consider giving palliative 
chemotherapy. The answers to this specific question were very haphazard without any clear pattern 
(figure 3). However the weighted average of each option remained above 3, and there were more 
respondents who would recommend palliative chemotherapy in all the categories than those who 
would not. This is explained in figure 4 where the neutral responses were removed and those who 
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Figure 4: Comparing recommendation of palliative chemotherapy depending on probability of death, grouping 
positive and negative responses 
 
 
4.3.2 Factors to consider when recommending palliative chemotherapy 
Question 16 included four factors that physicians may consider when recommending palliative 
chemotherapy. Respondents were asked to rate how important each of these factors were in their 
personal decision-making around recommending palliative chemotherapy. The answers are 
summarised in figure 5. Most respondents (92.7%) agreed that palliative chemotherapy should be 
given to maximise quality of life. About half of the respondents (48.7%) either agreed or strongly 
agreed that maximising life expectancy is an important factor when considering palliative 
chemotherapy. Parental preference was also an important factor where 58.6% of respondents 
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Figure 5: Importance of factors to consider when recommending palliative chemotherapy 
 
 
Question 16 was followed by an open-ended question where respondents were asked to share other 
factors that they routinely prioritise when recommending palliative chemotherapy. A few themes 
emerged that can be summarised under the following headings: 
(1) Symptom control  
(2) Patient preference  
(3) Family context 
(4) Risk benefit ratio of proposed palliative chemotherapy 
(5) Availability and cost of drugs 
(6) Unrealistic expectations 
 
Theme 1: Symptom control 
Several respondents mentioned the importance of improving symptoms especially pain with the 
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Theme 2: Patient preference 
The preference of the patient him/herself was a recurrent theme that emerged. The age of the 
patient, current quality of life, and the patient’s own opinion on further chemotherapy seems to be 
an important consideration in many cases. The cultural beliefs of the patient were also mentioned. 
 
Theme 3: Family context 
The family as the patient’s closest support system clearly plays an important role in these type of 
decisions around palliative chemotherapy. Specific issues that were mentioned include: 
 Socio-economic demands on the family 
 Improving the patient’s condition to allow the family to come to terms with the diagnosis 
and prepare themselves 
 Burden of treatment on the family 
 Cultural and religious beliefs of family 
 Travel distance from hospital, ability to get patient to hospital, place of residence 
 Psychosocial support 
 Parent request for chemotherapy 
 
Theme 4: Risk benefit ratio of proposed palliative chemotherapy 
Patients with relapsed disease and no known “curative” options should be considered for palliative 
chemotherapy. However, the following important considerations were mentioned with regards to 
risk benefit ratio of palliative chemotherapy: 
 Type of cancer and sensitivity to simple oral therapy 
 Toxicity of proposed treatment, minimal side-effects 
 Ease of use, no need for IV access 
 Cost of treatment relative to what is gained 
 
Theme 5: Availability and cost of drugs 
Availability of oral chemotherapy specifically, but also the cost of treatment were mentioned as 
important considerations. The availability of bone marrow donors and the issue of private medical 
aid support were also mentioned. 
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Theme 6: Unrealistic expectations 
A last but important factor was mentioned – continuing with chemotherapy treatment may 
perpetuate unrealistic patient expectations and physicians may find it easier to continue disease-
directed chemotherapy than to have the difficult discussions with patients and parents. In this 
situation, the fact that the chemotherapy is given for its palliative benefit (quality of life, symptom 
control) may not be made clear to the family and they may be under the false impression that the 
aim of the treatment is still curative. 
 
4.3.3 Factors to consider when choosing a specific palliative chemotherapy regimen 
Figure 6: Importance of factors when deciding on palliative chemotherapy regimen 
 
Question 20 assessed the factors that physicians may consider when choosing a specific palliative 
chemotherapy regimen. Respondents were again asked to rate how important each of these factors 
6.56 6.22
5.73 5.68 5.63 5.54
5.1
Weighted Average
Q20 When choosing a particular palliative chemotherapy regimen, 
rank the importance of the following factors
Toxicity of the chemotherapy regimen
Likely effectiveness of the chemotherapy regimen
Previous experience with the disease
Financial or social resources of the patient or the family
Utilization of medical resources
Perceived preferences of the family
Parental religious or cultural beliefs regarding disease or medical
treatments
BCHANE001 
 Page 46 of 99 
were in their personal decision making around choosing a specific palliative chemotherapy 
regimen (these regimens may include oral or intravenous drugs, in-hospital or outpatient treatment, 
different type of drugs and frequency of treatment). In figure 6, these factors are depicted in order 
of most important to least important as viewed by respondents. A weighted scale was used to ask 
the question with 1 being not at all important, and 7 being extremely important. All seven factors 
had a weighted average of more than 5, showing that these were all important factors in the 
decision making process. However, the two most important factors were the toxicity of the regimen 
and the likely effectiveness (both scoring at more than 6 – very important). Of these seven factors, 
the one ranked least important was the parental religious of cultural beliefs around the disease and 
medical treatments.   
 
4.3.4 Purpose of palliative chemotherapy  
The last general question assessed the usefulness or purpose of palliative chemotherapy. 
Respondents were asked what their perceived effect was of palliative chemotherapy (in general) 
with regards to some specific aims. Figure 7 shows a summary of the five aims of palliative 
chemotherapy, and an overall positive opinion with most respondents agreeing that palliative 
chemotherapy improves all five these areas of patient care. Only 12.2% of respondents disagreed 
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4.4 Palliative chemotherapy experience with most recent patient 
In the final part of the survey, participants were asked to consider their most recent patient for 
whom they prescribed palliative chemotherapy and answer the questions with that specific patient 
in mind. The patient may or may not have died. The patient’s age and diagnosis were asked, as 
well as the type of chemotherapy regimen. Factors which influenced the decision to prescribe 
palliative chemotherapy were elicited, specifically whether it was given primarily for the purpose 
of parental wishes. In those cases where the patient had died, the number of chemotherapy 
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Table 2: Characteristics of most recent patients who received palliative chemotherapy 
 n % 
Age   
<1 year 2 4.9% 
1 – 5 years 11 23.8% 
5 – 12 years  16 39.0% 
>12 years  12 29.3% 
Diagnosis   
Solid tumour, not CNS 29 70.7% 
Leukaemia/Lymphoma 8 19.5% 
CNS tumour  4 9.8% 
How long have you been this patient’s primary oncologist?   
0 – 6 months  10 24.4% 
7 – 12 months 14 34.2% 
13 – 24 months  7 17.1% 
> 24 months 10 24.4% 
How was the chemotherapy administered?   
Outpatient oral medication 28 68.3% 
Outpatient intravenous medication 5 12.2% 
Inpatient intravenous medication requiring 1-2 days hospitalisation 6 14.6% 
Inpatient intravenous medication requiring >2 days hospitalisation 2 4.9% 
Did the patient receive any palliative chemo primarily for the 
purpose of parental wishes? 
  
Yes 8 19.5% 
No 33 80.5% 
Has the patient died?   
Yes 26 63.4% 
No  14 34.1% 
Unsure 1 2.4% 
   
CHARACTERISTICS OF THE 26 PATIENTS WHO DIED N=26  
Time to death   
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<1 week 0 0% 
1-4 weeks 1 3.9% 
1-3 months 7 26.9% 
4-6 months 5 19.2% 
6-12 months 8 30.8% 
>12 months 5 19.2% 
Number of palliative chemotherapy regimens received prior to 
death 
  
1 regimen 16 61.6% 
2 regimens 4 15.4% 
3 regimens 3 11.5% 
4 regimens 3 11.5% 
When did patient receive the last chemotherapy   
Last day of life 0 0% 
Last week of life, but not on the last day 5 19.2% 
Last month of life, but not in the last week 12 46.2% 
Last three months, but not in the last month 9 34.6% 
Location of death   
Home 14 53.9% 
Hospital 12 46.1% 
 
The 41 respondents all answered the questions about their most recent patient for whom they 
prescribed palliative chemotherapy (see table 2). Most of the patients had solid tumours (70.7%) 
with 19.5% with leukaemia and lymphoma, and only 9.8% brain or CNS tumours. Age categories 
from 1 to over 12 years were well represented but the largest group was the 5-12 year age group 
(39.0%). Most patients received outpatient oral palliative chemotherapy (68.3%) with only 8 
patients (19.5%) requiring hospitalisation for inpatient intravenous chemotherapy. Chemotherapy 
was administered primarily for parental wishes in only 8 cases (19.5%). Timing of the start of 
palliative chemotherapy from the time of fist diagnosis differed widely, ranging from at the time 
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4.4.1 Factors which influenced the decision to prescribe palliative chemotherapy 
In question 25 respondents were asked how important the same factors discussed in question 20 
(figure 6) were when deciding on chemotherapy regimen were for this specific patient. The most 
important deciding factor remained toxicity of the chemotherapy regimen, but now the family 
preferences moved up in importance. The difference between physicians’ treatment considerations 
in general compared to treatment considerations for their most recent patient was calculated. The 
mean and ranges of responses together with the standard deviations are shown in table 3. 
 
Table 3: Differences in rating of palliative chemotherapy aims in general compared to aims achieved for most 
recent patient 
  
Importance of treatment 
factors in prescribing PC in 
general (1= not at all 
important to 5 = extremely 
important) 
Importance of treatment 
factors in prescribing PC 
for most recent patient (1= 
not at all important to 5 = 
extremely important) 
Treatment considerations when prescribing 
palliative chemotherapy Mean Std. dev. Mean  Std. dev. 
Toxicity of chemotherapy 4.56 0.50 4.51 0.67 
Effectiveness of chemotherapy 4.37 0.48 4.15 0.65 
Previous experience with the disease 4.20 0.45 3.90 1.10 
Family preferences 3.93 0.46 3.76 0.82 
Financial resources of family 3.98 0.84 3.73 0.96 
Use of medical resources 4.07 0.46 3.55 0.80 
Religious beliefs of family 3.70 0.80 3.29 0.92 
 
 
4.4.2 Effects of palliative chemotherapy for specific patient 
Question 28 was designed to compare the aims and perceived effects of palliative chemotherapy 
in general (asked in question 19, see figure 7) with the effects of palliative chemotherapy on a 
specific patient. The difference between physicians’ aims with palliative chemotherapy in general 
was compared to whether these aims were met for their most recent patient and calculated. The 
mean and ranges of responses together with the standard deviations are shown in table 4. Overall, 
there was only a small difference in the perceived effects of palliative chemotherapy in general 
compared to the effects experienced with the specific patient. Increase in lifespan was slightly 
higher than perceived, with improvement in quality of life reported in the specific patient to be as 
good as was expected in general. 
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Table 4: Differences in rating of palliative chemotherapy aims in general compared to aims achieved for most 
recent patient 
  
Importance of aim in prescribing 
PC in general (1= not at all important 
to 5 = extremely important) 
Did PC accomplish aim for most 
recent patient (1= not at all important 
to 5 = extremely important) 
Aims of palliative chemotherapy Mean Std. dev. Mean  Std. dev. 
Increase length of life 3.38 0.79 3.61 1.10 
Improve/enhance quality of life 4.02 0.64 3.98 0.92 
Maintain quality of life 3.88 0.74 3.78 0.95 
 
 
4.4.3 Toxicity related events as a result of palliative chemotherapy for specific patient 
The last question looked at whether the patient suffered from any toxicity related events as a result 
of the palliative chemotherapy. Almost half of the patients (43.9%) had additional sick visits to 
the clinic, with 22% of patients needing hospital admission for toxicity related side effects. None 
of the patients needed ICU level care. Eleven patients (26.8%) needed invasive procedures due to 
toxicity. Only two patients (5%) died due to chemotherapy related toxicity.   
 
4.4.4 Experience with palliative chemotherapy in patients who had died at time of survey 
The second part on the survey asked the respondents to answer questions specifically about the 
most recent patient for whom they had prescribed palliative chemotherapy (see table 2). Twenty-
six (63.4%) of these patients had died at the time of the survey. Among these 26 patients, 38.4% 
had received more than one palliative chemotherapy regimen prior to their death. Furthermore, 
19.2% of this group of patients had received chemotherapy in the last week of life, and 65.4% 
were receiving chemotherapy in the last month of life. About half the patients (53.9%) died at 
home, and the other half 46.1% died in hospital.  
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CHAPTER 5: Results of file review 
5.1 Introduction 
Chapter 5 presents the results of the file review that was done to assess the use of palliative 
chemotherapy in the Steve Biko Academic Hospital paediatric oncology unit over the period 
January 2012 to December 2018 (7 years). 
 
5.2 File selection 
Figure 8: Process of file selection for review 
                                                     
 
Figure 8 explains how the files of patients who received palliative chemotherapy were selected to 
be included in the file review. Of the 305 patients who died in this 7 year period, 282 (92.5%) were 
oncology patients. Of the oncology patients, 195 (69.1%) died of progression of disease, 78 
patients (27.7%) died of treatment related complications, and the remaining nine patients died of 
causes unrelated to their primary cancer diagnosis. The group who died of progression of disease 
(195 patients) included patients who died while on active treatment with curative intent, as well as 
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patients who died within the first three days of admission. Out of this group of 195 we selected the 
files of the patients who received palliative chemotherapy, this came to a total of 74 files (37.9% 
of the 195 patients who died of progression of disease, and 26.2% of the total group of 282 
oncology patients who died during this 7 year period). There were 3 patients in total who were 
treated with palliative radiotherapy, and did not receive any chemotherapy. 
 
5.3 Demographic data 
5.3.1. General characteristics 
Table 5 shows the general characteristics of the 74 patients who received palliative chemotherapy. 
The median age at diagnosis was 6.0 years with a range of 0.3 to 17.6 years. There were more 
males (60.8%) than females and most of the patients (56.8%) were residing in Mpumalanga 
province. Only eight of the patients (10.8%) had no parents, and almost half of the patients (48.6%) 
were cared for by both parents.  
The location of death was at home for just more than half of the patients (52.7%). About a third 
(35.1%) of the patients died in the oncology unit and 10.8% in the local hospital (closer to home). 
Only one patient, a 16 year old adolescent with osteosarcoma, died in the local hospice. 
 
Table 5: General characteristics of patients included in file review (n=74) 
CHARACTERISTICS n  % 
Gender      
Male 45  60.8% 
Female 29  39.2% 
    
Age at diagnosis (years)    
Median  6.0  
Range  0.3-17.6  
    
Age at death (years)    
Median  7.1  
Range  1.7-18.8  
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Province of residence    
Gauteng 28  37.8% 
Mpumalanga 42  56.8% 
Limpopo 2  2.7% 
North West 2  2.7% 
    
Family structure    
Both parents alive and well 56  75.7% 
Mother only 6  8.1% 
Father only 3  4.1% 
No parents 8  10.8% 
Not documented 1  1.4% 
    
Primary caregiver    
Both parents 36  48.6% 
Mother 23  31.1% 
Father 2  2.7% 
Grandparent(s) 6  8.1% 
Sibling 4  5.4% 
Other 3  4.1% 
    
Place of death    
Home 39  52.7% 
Oncology ward in treating hospital 26  35.1% 
Hospital closest to home 8  10.8% 
Hospice 1  1.4% 
 
 
5.3.2 Location with reference to oncology unit and local hospital 
Figure 9 and 10 illustrate the addresses of the patients included in this review (each star represents 
a patient’s home address). Their average distance to the local hospital was 16.4 km, with the 
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furthest being 94 km. The average distance to the oncology unit was 164.2 km, with 24 patients 
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5.3.3 Cancer diagnoses of patients  
Figure 10 illustrates the cancer diagnoses of the 74 patients, with the three most common diagnoses 
being neuroblastoma (18.2%), retinoblastoma (15.6%) and osteosarcoma (14.3%). Comorbidities 
that were recorded in the files included human immunodeficiency virus (HIV) infection in 11 
patients (14.3%), and one patient each with diabetes mellitus, haemophilia A (severe) and Fanconi 
anaemia.  Of the eleven patients with HIV infection, eight patients had HIV-related malignancies 
(seven with Kaposi sarcoma and one patient with non-Hodgkins lymphoma). The other three 
patients with HIV disease had malignancies most likely not related to the HIV, which were 
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retinoblastoma, osteosarcoma and acute lymphoblastic leukaemia. The patient with Fanconi 
anaemia developed acute myeloblastic leukaemia.  
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5.4 Initiation of palliative chemotherapy 
 
Table 6: Initiation of palliative chemotherapy in the oncology unit at SBAH 
 n % 
Stage of disease at initiation of palliative chemotherapy   
As first line treatment 47 64.9% 
At time of first relapse 19 24.7% 
At time of second relapse 7 9.1% 
At time of third relapse 1 1.3% 
   
Diagnosis of patients who received palliative 
chemotherapy as first line treatment (n=47) 
  
Neuroblastoma stage IV 13 27.7% 
Retinoblastoma stage IV and V 11 23.4% 
Metastatic osteosarcoma 10 21.3% 
Kaposi sarcoma – widespread multi-system disease 6 12.8% 
Brain tumours 2 4.3% 
Metastatic rhabdomyosarcoma 2 4.3% 
Metastatic Ewing sarcoma  1 1.3% 
Desmoplastic small round cell tumour (DSRCT) 1 1.3% 
Metastatic nasopharyngeal carcinoma 1 1.3% 
 
5.4.1 Stage of disease when palliative chemotherapy was initiated 
Table 6 summarises the different aspects of the initiation of palliative chemotherapy in the unit 
over the past 7 years.  The first aspect looks at the stage in the disease trajectory when the decision 
was made to initiate palliative chemotherapy. In 47 patients (63.5%) the disease was deemed 
incurable at diagnosis, and chemotherapy given for the purpose of palliation. A total of 27 patients 
were given palliative chemotherapy at relapse of disease; of these 19 (25.7%) patients were at first 
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5.4.2 Time from diagnosis to initiation of palliative chemotherapy 
Table 7: Time from diagnosis to start of palliative chemotherapy 
 




All patients included  74 0.1 0-7.2 
As first line treatment  47 0.1 0-1.5 
At time of first relapse  19 1.1 0.3-6.4 
At time of second relapse  7 2.8 1.0-7.2 
At time of third relapse  1 3.4  
 
A summary of the time from diagnosis to initiation of palliative chemotherapy is shown in table 
7.  Because more than half of the patients received palliative chemotherapy as a first line treatment, 
the median time to start of palliative chemotherapy in the whole group together is 0.1 years (1.2 
months, or 36 days). However when divided into groups the median time to start palliative 
chemotherapy becomes longer with the subsequent relapses. The longest time from diagnosis to 
start of palliative chemotherapy was 7 years and 3 months in a patient with acute promyelocytic 
leukaemia who relapsed for the second time.  
 
5.4.3 Decision, documentation and aims of palliative chemotherapy 
The decision to change the treatment aim to palliative was documented in all the files reviewed. 
The files were scrutinised to see whether there was documentation of any family discussion around 
this decision, and only just more than half of the files (40 files, 54.1%) had clear documentation 
of a discussion with parents, caregiver or family.  
Six possible aims of palliative chemotherapy were included in the datasheet used to capture data 
from the files. These aims were documented in the patient files as part of the documentation of the 
decision for palliative chemotherapy. Figure 11 illustrates the findings around the main aims of 
using palliative chemotherapy in these 74 patients. The most important reason for using palliative 
chemotherapy in this group of patients was to improve symptom control, this was a documented 
aim in 97.3% of patients. The opinion of the parents played an important role in 32.9% of the 
cases. There were three documented cases where the parents insisted on chemotherapy (this was 
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intravenous in-patient chemotherapy) against the advice of the treating oncologist, and it was 
administered as palliative chemotherapy. 
 

























Aims of palliative chemotherapy
BCHANE001 
 Page 61 of 99 
5.5 Palliative chemotherapy regimens 
5.5.1 Palliative chemotherapy regimens according to diagnosis 
Table 8 summarises the palliative chemotherapy regimens used in the 74 patients whose files were 
reviewed. It includes the need for admission (in or outpatient treatment) as well as the number of 
cycles of chemotherapy administered. Of the total group of 74 patients, 55 (74.3%) received 
intravenous and/or intrathecal treatment (with of without oral chemotherapy), while the remaining 
19 (25.7%) received only oral palliative chemotherapy. Inpatient chemotherapy needing prolonged 
admission to hospital with the risk of neutropaenic sepsis were administered to 27 of the 74 patients 
(36.5%), mostly the patients with osteosarcoma (10 patients) and neuroblastoma (10 patients).  
 





Inpatient or outpatient 
ALL 9   
Combinations of oral chemotherapy including: 




Prednisone, 6-thioguanine and vincristine 1 PO/IV Outpatient 
Prednisone and intrathecal chemo 2 PO/IT Outpatient 
    
AML 8   
Combinations of oral chemotherapy including: 
Prednisone, 6-thioguanine, 6-mercaptopurine 
6 PO 
Outpatient 
6-thioguanine and cytarabine 1 PO/IV Outpatient 
6-thioguanine and intrathecal chemo 1 PO/IT Outpatient 
    
Non-Hodgkins lymphoma 2   




    
Neuroblastoma 14   
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Rapid COJEC (time intense) 3 IV  Inpatient 
Rapid COJEC with surgery and radiotherapy/MIBG 4 IV Inpatient 
Rapid COJEC followed by second line chemo (VEC 
or oral cyclophosphamide) 
2 PO/IT 
Inpatient 
COJEC or OPEC/OJEC every 3 weeks 2 IV Inpatient 
VEC chemotherapy 1 IV Outpatient 
Oral cyclophosphamide 2 PO Outpatient 
    
Osteosarcoma 11   
EURAMOS MAPIE (five drug combination) 3 IV Inpatient 
EURAMOS MAP (three drug combination) 7 IV Outpatient 
Oral cyclophosphamide 1 PO Outpatient 
    
Retinoblastoma 12   
VEC chemotherapy 7 IV Outpatient 
VEC chemotherapy + IT 4 IV Outpatient 
VEC chemotherapy + radiotherapy 1 PO Inpatient 
    
Kaposi sarcoma 7   
Prednisone/Vincristine/Bleomycin/Daunorubicin 7 IV Outpatient 
    
Brain tumours 3   
VEC chemotherapy 3 IV Outpatient 
    





VAC 1 IV Outpatient 
Cyclophosphamide 1 PO Outpatient 
    
Nasopharyngeal carcinoma 1   
5-FU, Cisplatin, Radiotherapy 1 IV Inpatient 
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Desmoplastic small round cell tumour 1   
VEC chemotherapy 1 IV Outpatient 
    
Ewing sarcoma 1   
VEC chemotherapy and radiotherapy 1 IV Inpatient 
    
Nephroblastoma    
ICE chemotherapy 1 IV Inpatient 
 
 
5.5.2 Effect of palliative chemotherapy on survival time 
Figure 13: Survival curve starting with the date of the initiation of palliative chemotherapy 
 
 
Figure 12 shows the survival curve for the period between the initiation of palliative chemotherapy 
and death. The median duration of this interval between the initiation of palliative chemotherapy 
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and death was calculated to be 174 days (range 0-910 days). Survival curves according to 
diagnosis, from initiation of palliative chemotherapy, is illustrated in figure 13.  
Table 9 summarises the median duration and range of the interval between the initiation of 
palliative chemotherapy and death for the three most common solid tumours (neuroblastoma, 
retinoblastoma and osteosarcoma) - the median time from initiation of palliative chemotherapy 
until the time of death was around 225 days (7 months) while the median for the haematological 





Figure 14: Survival curve for patients on palliative chemotherapy 
BCHANE001 
 Page 65 of 99 
Table 9: Time from the start of chemotherapy until death for the five most common diagnoses 
Diagnosis 




Neuroblastoma 14 232 72-803 
Retinoblastoma  12 248 15-703 
Osteosarcoma  11 213 21-610 
ALL  9 84 17-714 
AML 8 91 10-349 
 
 
5.6 Cessation of palliative chemotherapy 
5.6.1 Decision, documentation and reason for stopping palliative chemotherapy 
The decision to stop palliative chemotherapy was documented clearly in 28 of the 74 files (37.8%), 
and 25 of the 74 files (33.8%) had documentation of an end of life discussion with the family. 
These were not all the same files as the ones who had a documented decision to stop palliative 
chemotherapy. 
Reasons recorded for stopping chemotherapy are represented in table 10.  The ten patients who 
completed the planned number of cycles had the following diagnoses: retinoblastoma (4 patients 
completed 6 cycles of VEC chemotherapy), neuroblastoma (2 patients completed the rapid COJEC 
protocol), osteosarcoma (2 patients completed the 5-drug MAPIE protocol ), Kaposi sarcoma (one 
patient completed 6 cycles of treatment), and nasopharyngeal carcinoma (one patient received the 
full treatment of 5FU with cisplatin for 3 cycles and radiotherapy). 
Table 10: Reasons recorded for stopping palliative chemotherapy 
Reasons for stopping palliative chemotherapy n=28 % 
Progression of disease while on PC 15 53.6% 
Completed the planned protocol of PC 10 35.7% 
Too much financial stress on the family 1 3.6% 
Side-effects from PC 1 3.6% 
Absconded 1 3.6% 
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5.6.2 Time from end of palliative chemotherapy to death 
The median time from the last palliative chemotherapy to the time of death was 30 days (range 0-
742 days) for the whole group of patients. When separated into groups of patients with solid 
tumours (55 of 74, 74.3%) and those with leukaemia/lymphoma (19 of 74, 25.7%), the median 
time from last palliative chemotherapy for solid tumour patients was 40 days (range 0-742 days). 
Of the 19 patients with leukaemia/lymphoma, 17 (89.5%) were on oral palliative chemotherapy at 
the time of death, while only 6 of the 55 patients with solid tumours (10.9%) died while on 
palliative chemotherapy. 
 
Of the total group of 74 patients, 38 (51.4%) received palliative chemotherapy in the last 30 days 
of life. However, when separated again into the two groups (solid tumours and those with 
leukaemia/lymphoma), only 21 of the 55 patients with solid tumours (38.2%) received palliative 
chemotherapy in the last 30 days of life.  
 
5.6.3 Outcome of palliative chemotherapy with regards to quality of life 
Although no formal assessment of quality of life was done in these patients, improvement in 
symptoms and activity level was recorded as improvement in QOL in this file review. Just more 
than half of the patients (41 of 74, 55.4%) had documentation of symptomatic improvement in 
their files when reviewed. 
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CHAPTER 6: Discussion 
6.1 Introduction 
The study’s main aims were to describe paediatric oncologists in South Africa’s perspectives and 
practices regarding palliative chemotherapy, and to investigate the use of chemotherapy at the end 
of life in patients treated at the SBAH paediatric oncology unit. The researcher demonstrated that 
paediatric oncologists in South Africa are using palliative chemotherapy mostly with the aim of 
improving quality of life. From the single centre experience, patients may benefit from palliative 
chemotherapy with regards to prolonging life as well as quality of life, but they need to be selected 
carefully and the intention of treatment made clear from the onset. A discussion follows on the 
findings of the survey as well as that of the file review. 
 
6.2 Recommending palliative chemotherapy 
A few questions in the survey looked at different issues around whether or not to recommend 
chemotherapy. In all these questions, a majority of the paediatric oncologists were either neutral 
or agreed that palliative chemotherapy should be recommended. Those with a truly negative 
attitude towards the use of palliative chemotherapy were in the minority.  
 
Concerning factors that physicians may consider when recommending palliative chemotherapy, 
the most important treatment considerations and aims were to minimise toxicity of the 
chemotherapy regimen and to improve quality of life. Parental preference was in general not 
reported to be one of the most important factors when deciding on palliative chemotherapy. This 
is in contrast to the original study by Kang et al(2) done in the USA using this same survey, where 
adherence to parent preferences ranked as the second most important consideration after toxicity, 
when prescribing palliative chemotherapy. Compared to the findings by Kang et al, where 40.8% 
of patients received palliative chemotherapy primarily for parental wishes, in our study only 19.5% 
of patients received treatment primarily because the parents requested it. There may be different 
reasons why parental preference was less important than in the USA survey. South African parents, 
especially the majority of patients treated in government hospitals, may not have the same level of 
knowledge and empowerment, and the access to information is likely to be less than that in the 
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USA. The question also arises whether South African oncologists are still managing patients in a 
more paternalistic manner than their USA counterparts. 
 
In our study, the most important treatment considerations were largely achieved as expected in the 
most recent patient treated with palliative chemotherapy. There was no great difference between 
the aims and treatment considerations in general, and the achievement of these aims and treatment 
considerations as reported for the most recent patient. Again, this differs from the Kang study 
where the treatment considerations and aims were not achieved to the degree expected in the 
experience with the most recent patient. In the much larger group of oncologists in the USA (a 
total of 422 participants), they found that a decrease in symptoms and maintaining or improving 
quality of life was not achieved as expected.  
 
Individual opinions and preferences differ greatly with regards to recommending palliative 
chemotherapy - this had been examined in various studies examining health care professionals’ 
opinions on palliative chemotherapy.(2,18,33,43,44) Results from Wusthoff et al(19) specifically 
demonstrated a large variability in treatment goals, perceived chances for cure as well as the degree 
to which further curative intervention would be considered desirable for each patient. Our study 
also showed that for most respondents (36/40, 90%), their individual preferences regarding the use 
of palliative chemotherapy sometimes or often differs from that of their colleagues. The lack of 
evidence-based guidelines in the field of palliative chemotherapy, especially in children, causes 
physicians to rely on their previous experience, perceptions of toxicity, and parents’ opinion to 
make these very difficult recommendations. 
 
Parents have reported in some studies (32,45) that the most significant factor in their decision 
making around palliative chemotherapy was the opinion and recommendation of the treating 
oncologist. This emphasises the importance for the oncologist of examining beliefs about benefits 
and burdens of palliative chemotherapy, and the aims and goals of prescribing it to patients in 
situations where disease-directed treatment may be questioned. By involving the paediatric 
oncology community in completing this survey, it would be an unexpected benefit if this study 
could be the start of discussions around these sometimes controversial decisions.  
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6.3 Palliative chemotherapy patients: Comparing SA to the USA 
When comparing the USA group of patients reported on in the survey Kang et al, some of the 
important differences included: significantly more patients with CNS tumours treated with 
palliative chemotherapy in the USA compared to South Africa, and more patients in the USA had 
received second, third and fourth line chemotherapy regimens before being started on palliative 
chemotherapy. Administration routes and admission for palliative chemotherapy were comparable 
between the two surveys. The number of osteosarcoma and neuroblastoma patients receiving 
intense intravenous chemotherapy in the SBAH group caused a much higher number of these 
patients to need admission for intravenous chemotherapy (although the aim was still palliative).  
 
Surprisingly, there were many similarities between the patients discussed by respondents as the 
“most recent patient” in the two surveys. These similarities included period from last 
chemotherapy to time of death, administration routes and admission for palliative chemotherapy, 
as well as place of death. It is the hope of the researcher that these similarities across continents 
and settings are a reflection of the paediatric oncologists’ inherent value systems that should be 
guiding all medical decision-making, to do what is best for the patient and family. 
 
6.4 Demographic details of patients who received palliative chemotherapy at 
the SBAH oncology unit 
The demographics of this group of patients are a good representation of the demographics of all 
patients treated in the oncology unit in SBAH. Childhood cancer is more common in males with a 
ratio of boys to girls of 1.2 reported in a large epidemiological study published in 2010,(46) so the 
male predominance of 60.8% is expected. The median age of 6.0 years in our group is also close 
to the 5 years 10 months reported in the epidemiological study. As expected when looking at the 
demographics of patients treated in the unit, more than half of the patients were from Mpumalanga 
province and a third of the patients included in this review travelled more than 200km to receive 
oncology care and palliative chemotherapy. The role that this distance from the oncology unit 
plays in the provision of palliative care and decisions around palliative chemotherapy has not been 
explored and the researcher could not find any literature that specifically asked questions around 
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distance from oncology units and its effects on quality palliative care. It is our impression and 
concern that the time and financial implications of travel may have a direct impact on the quality 
of life of the family, and should be a consideration in decision making about palliative 
chemotherapy and end of life care plans. 
 
6.5 The role of HIV in patients receiving palliative chemotherapy 
South Africa is still one of the countries with the largest HIV epidemics in the world. In 2017, 19% 
of adults in South Africa were living with HIV. The prevalence reported for the 0-14 year age 
group in the 2017 statistics was 2.7%.(47) In our group of patients who received palliative 
chemotherapy, 11 of 74 (14.9%) were HIV infected, with eight of the infected patients having 
HIV-related malignancies (Kaposi sarcoma, Non-Hodgkins lymphoma). This is a high prevalence 
when compared to the national prevalence figures, however, these patients have HIV-related 
malignancies so it is expected that the rate of HIV infection in this group of patients who died due 
to childhood cancer will be higher. It has been well documented that HIV infection predisposes 
children to the development of malignancies, and that without effective antiretroviral treatment the 
prognosis of HIV-related malignancies is dismal.(48) However, with the use of ART the outcomes 
of these children are much improved. 
 
6.6 Palliative chemotherapy as first line disease-directed treatment 
Palliative chemotherapy as first-line treatment is commonly used and labelled as palliative in adult 
oncology settings with incurable tumours with metastases including metastatic breast cancer, 
upper gastrointestinal cancer, pancreatic cancer and colorectal cancer.(25) However, the researcher 
struggled to find paediatric literature willing to label first-line chemotherapy as palliative in the 
setting of childhood cancer. There may be many reasons for this but most importantly, childhood 
tumours tend to be more chemo-sensitive than those seen in adults. It is also a possibility that 
paediatric oncologists may struggle to call treatment “palliative” from the onset of treatment. One 
article on the management of soft tissue sarcomas did mention clearly that although metastatic soft 
tissue sarcoma may respond to chemotherapy, there is limited evidence that chemotherapy 
improves overall survival, and it is, therefore, considered to be palliative therapy in this setting.(49) 
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6.6.1 Palliative chemotherapy as first line treatment for metastatic osteosarcoma 
For the purpose of selecting patient files to include in the review, we included all the patients who 
had what we deemed to be incurable disease at the time of presentation. This included patients 
with osteosarcoma (with extensive metastatic disease or inoperable primary tumours e.g. extensive 
iliac bone involvement) who received the same intense chemotherapy regimen as would be used 
for patients with localised disease. However, it was made clear from the time of diagnosis, and 
documented in the patient file, that the aim of the intense chemotherapy was palliation. Only two 
of the eleven patients with osteosarcoma manage to complete the full protocol, all the other had 
progression of disease while on chemotherapy and improvement in QOL was documented in less 
than half the patients treated with chemotherapy. This type of intense intravenous in-hospital 
chemotherapy could lead to prolonged admissions, which may have a profoundly negative impact 
on the QOL of the patient in the last months of life. It may be advisable to give a limited number 
of cycles and assess the response rather than committing to treat extensive metastatic osteosarcoma 
with a full course of chemotherapy. There is not enough evidence yet to suggest that oral 
metronomic chemotherapy can be used with positive effect, but Zapletalova et al did report some 
palliative effect in osteosarcoma patients treated with the COMBAT regimen.(13) 
 
6.6.2 Palliative chemotherapy as first line treatment for stage IV neuroblastoma 
The group of stage IV neuroblastoma patients differed from the osteosarcoma group in that only 
about a third of them (5/14, 35.7%) received only intense chemotherapy. A further six of the 
patients also received intense chemotherapy, which was followed by one or more of the following 
treatment modalities: surgery, MIBG treatment, external beam radiotherapy and/or oral 
chemotherapy. This was all given with palliative intent and patients had a good response with 
regards to improvement in QOL (12/14, 85.7%). It is well described in the literature that cure rates 
for stage IV neuroblastoma are low, but that patients may initially respond well to chemotherapy 
before eventually relapsing.(42) At the time of relapse there are more options for palliative 
management including MIBG treatment, external beam radiation and further chemotherapy (e.g. 
oral cyclophosphamide together with topotecan or irinotecan, as well as temozolamide). Relapsed 
disease has a 5-year overall survival of <10%. 
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Our experience with the mixed regimens we used as palliative chemotherapy in this group of 
patients with stage IV neuroblastoma showed good improvement in quality of life in most patients, 
allowing them good QOL and time at home with families before the inevitable relapse and eventual 
death. No patient has survived a diagnosis of stage IV neuroblastoma in our unit in the past seven 
years. 
 
6.6.3 Palliative chemotherapy as first line treatment for stage IV retinoblastoma 
Treatment of overt extraocular or intracranial retinoblastoma with palliative chemotherapy from 
the time of diagnosis is a less controversial topic. The SIOP-PODC guidelines(50) clearly state 
that even though the chances of cure are very poor, that the tumour is very chemo-sensitive, so 
palliative chemotherapy usually has a significant role in improving quality of life (shrinking the 
fungating exophytic tumours and improving pain significantly). These guidelines state that 
standard-dose chemotherapy with an intention of prolonging life should be offered to children with 
stage IV disease. The combination of vincristine, etoposide and carboplatin (VEC) does not often 
cause significant toxicity and can be administered as outpatient intravenous chemotherapy. The 12 
patients included in our study all received this VEC chemotherapy (between one and nine cycles), 
and four patients also received intrathecal chemotherapy. One patient received external beam 
radiation as well.  
 
Our experience with treating these patients concur with what is stated in the SIOP-PODC 
guidelines, improved quality of life was documented in 8 of the 11 patients (72.7%). We have 
subsequently extended our use of VEC chemotherapy in the palliative setting to some other 
diagnoses (brain tumours, hepatoblastoma) because of the low toxicity, ease of administration and 
positive experience in the patients with advanced retinoblastoma. 
 
6.7 Goals of palliative chemotherapy 
In all 74 patient files, the decision to give chemotherapy with the aim of palliating was 
documented. Only 54.1% of the files had a documented family discussion to prove that this change 
in the disease and treatment trajectory was explained and discussed with them. Our datasheet 
included seven possible options as considerations when making the decision to start palliative 
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chemotherapy, and it can be compared to the findings of Tomlinson et al who reported on the same 
seven factors as indicated by 128 health care professionals working in Toronto, Canada, in 
interviews. In comparison, the different factors were ranked in the same order of importance, with 
only the opinion of health care professionals rated more important in the SBAH group. This was 
due to semantic differences in how the question was viewed – the Toronto study asked the 
importance of the opinion of other health care professionals, while the SBAH study considered the 
health care professional’s own opinion of the proposed palliative chemotherapy. Excluding the 
health care professional’s opinion, the three most important considerations for both these settings 
were the child’s quality of life, increase in survival time and hope. 
 
6.8 When should palliative chemotherapy be stopped? 
Palliative chemotherapy was stopped for different reasons in the SBAH group. Progression of 
disease while on chemotherapy is a clear indication that the chemotherapy is not having the desired 
effect, and then it should be strongly considered rather not to offer further treatment with possible 
toxicity.  
Almost all the patients with leukaemia/lymphoma died while on oral chemotherapy. It can become 
a difficult decision when to stop the oral “leukaemia maintenance”-type chemotherapy for these 
patients as toxicity is minimal and the disease can progress slowly for a long time before suddenly 
decompensating.  
 
In adult palliative chemotherapy literature there is a continuous debate around the inappropriate 
use of chemotherapy in the last 30 days of life.(22–25) It is the opinion of the researcher that this 
argument may not have the same validity in the treatment of incurable childhood cancer, especially 
when the chemotherapy used with palliative intent does not have significant toxicity. In our group 
of solid tumour patients, the median time from stopping chemotherapy to the time of death was 40 
days, and 21 of the 55 patients (38.2%) received chemotherapy within the last 30 days of life. Of 
these 21 patients, 12 had improvement in symptoms because of the palliative chemotherapy. 
 
In ten of our patients, we elected to stop palliative chemotherapy because they had completed the 
protocols we were using (e.g. rapid COJEC). We have since learnt from experience that in patients 
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who responded well and who have good QOL the use of oral chemotherapy as maintenance after 
completion of intense chemotherapy may extend the time to relapse and may manage symptoms 
better for a longer period. 
 
6.9 Place of death 
More than half of the patients included in this study died at home, and only about a third died as 
inpatients in the oncology unit. There may be different reasons for the higher than usual amount 
of patients dying at home – it is our impression that these patients likely had more counselling and 
preparation for the likely outcome because of repeated palliative chemotherapy visits, and that the 
parents were better prepared for the patients dying at home. The study unfortunately did not include 
any detail on the end of life experiences of the patients and families, as detailed information on 
this was not available in their files. Future research into palliative chemotherapy will aim to include 
a discussion with parents on the end of life journey of each child and family. 
 
6.10 Limitations of the study 
Although the rate of response to our survey was excellent (41/46, 89.1%) the number of paediatric 
oncologists in the country is small and therefore the findings of this survey may not be significant. 
The fact that the survey was quantitative limited the amount of information that was gathered from 
the oncologists who responded. The accuracy of the answers about the most recent patient may 
not reflect their usual practice, since it specifically focuses on one patient. Furthermore, the self-
reporting format of the questionnaire can lead to both social desirability bias and recall bias.  Social 
desirability bias happens when participants answer questions in a way that they feel might be 
viewed favourable by others.  However, the responses were anonymous, which should have 
minimised social desirability bias. Recall bias remains a problem since oncologists might report 
what they would want to do instead of a reliable recollection of actual events in their practice.   
 
When reflecting on the wording of the questionnaire, there may be some concern about the clarity 
of the specific question related to patients needing ICU level care. The question did not take into 
account that patients may not be considered as candidates for ICU care due to their poor prognosis 
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– this has implications for the conclusion that none of the patients needed ICU level care. This 
question would have had more value if it was worded in such a way that respondents could answer 
whether or not the patient may have been offered ICU level care if there were no limitations on 
access to care or services. 
 
With regards to the file review, it was done retrospectively and there was no objective quality of 
life questionnaire or interview done to establish the QOL improvements. We looked at documented 
symptoms, clinic visits and admissions to hospital recorded in files to decide on the effect on QOL. 
Documentation of symptoms was done at each visit but not always with the same amount of detail. 
This remains a limitation and would be much more accurate if done as part of a prospective study.  
 
The file review was purely descriptive, and patients’ QOL and symptoms were recorded but not 
compared to a group of patients who did not receive chemotherapy as part of their palliative care. 
Due to the limited information available from the file review, we could not assess end of life events 
and the quality of deaths as this is not part of standard information recorded in the files. Reporting 
on symptom control and QOL will be much better if done as part of a prospective qualitative 
interview-based study. As discussed in the literature review, the perspective of parents and patients 
are extremely important when discussing palliative chemotherapy and making decisions about 
palliative treatment. Repeated qualitative measurements of the child and family’s QOL and its 
associations with palliative chemotherapy should be a research priority in future 
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CHAPTER 7: Conclusion and recommendations 
7.1 Implications of the findings 
The study met its aim in exploring how South African paediatric oncologists use palliative 
chemotherapy, and reporting on a single unit’s experience with palliative chemotherapy. Results 
of the study suggest that palliative chemotherapy plays a very important role in the management 
of children with incurable cancer, and that the aim of improving quality of life is reached in many 
patients by using palliative chemotherapy. However, the use of chemotherapy for the purpose of 
palliation is haphazard and protocols are greatly lacking, and oncologists are mostly relying on 
their own previous experience to make these very important decisions. Our findings should 
challenge paediatric oncologists in South Africa to carefully examine their expectations of the use 
of palliative chemotherapy in children with incurable cancer.    
 
7.2 Recommendations and further studies 
There is a lack of end-of-life research in paediatric oncology. This study provided a birds-eye view 
on the use of palliative chemotherapy in children, but also showed clearly that many decisions 
around end of life care and decision making are better researched using a qualitative, prospective, 
interview-based approach. Repeated measurements of the child and family’s QOL and its 
associations with palliative chemotherapy should be a research priority in future, especially in our 
setting where many of the patients are from indigent communities and travel very far to reach 
oncology care. These measurements should also include transport costs, time in hospital, and use 
of scarce resources.  The selection of patients more likely to benefit from palliative chemotherapy 
also needs to be researched, with the aim of identifying better predictive biomarkers.  
 
The role of introducing standardised protocols and guidelines for the use of palliative 
chemotherapy countrywide may be a worthwhile discussion to introduce to the community of 
paediatric oncologists in South Africa. A great advantage of the use of standardised protocols will 
be the collection of data in a larger group of patients that can eventually provide more information 
about efficacy of palliative chemotherapy. The fact remains, however, that the aims are not easily 
measurable and that there may be different goals of treatment for different families.  
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7.3 Plan for dissemination of findings 
Feedback concerning the file review will be given to the oncology unit staff and the paediatric 
department of SBAH, the plan is to do this at a departmental meeting.  
The researcher also plans to discuss the results at the biannual meeting of the SACCSG and plans 
to submit an abstract for presentation at the South African Clinical Oncology (SACO) meeting as 
well as submit an article for review and publication in a peer-reviewed journal such as Pediatric 
Blood and Cancer or the South African Medical Journal. An abstract will also be submitted to the 
international Paediatric Palliative Care conference happening in Rome in 2020. 
This research is relevant especially for LMIC faced with many patients presenting very late to 
health care facilities. The comparison of our survey to the same survey done in the USA will be of 
interest to the paediatric oncology community worldwide. It will also be important to discuss the 
results with palliative care specialists, not just the oncology community.  
 
7.4 Conclusion 
This study brings valuable new insight into the South African oncologist’s perspective on the use 
of palliative chemotherapy. Although the overall attitude towards the use of palliative 
chemotherapy is positive, there is great inter-individual variation in opinions and experience. Even 
the definition of palliative chemotherapy is still unclear and debatable. The lack of empirical data 
to justify recommendations concerning palliative chemotherapy remains a problem, and the 
researcher hopes that this study will spark productive discussion and planning towards more 
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APPENDICES 
APPENDIX 1: Online survey 
Title: Use of palliative chemotherapy in South Africa: National survey of 
paediatric oncologists and experience in a single unit. 
 
PALLIATIVE CHEMOTHERAPY SURVEY 
(Based on survey created by Tammy Kang and Chris Feudtner, The Children’s Hospital of 
Philadelphia, Pennsylvania) 
 




What is your age group?  30 – 39 years 
 40 – 46 years 
 47 – 52 years 
 53 – 68 years 
 69+ years 
 
 
Which of these categories best 
characterises your practice type? 
 Private practice 
 Academic 




Approximately how much of 
your time is spent on direct 
patient care? 
 < 20% 
 20 – 50% 
 51 – 75% 
 > 75% 
 
 
Approximately how much of 
your time is spent on direct 
patient care of oncology 
patients? 
 < 20% 
 20 – 50% 
 51 – 75% 
 > 75% 
 
 
How many years have passed 
since you completed your 
fellowship training in paediatric 
haematology/oncology 
 0 – 5 years 
 6 – 10 years 
 11 – 15 years 
 16 – 20 years 
 > 20 years 
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 Working as medical officer 
 Busy with fellowship training 
 
 
Of the oncology patients you 
have cared for, how many have 
died in the past year? 
 0 – 1 
 2 – 9  
 10+ 
 
Approximately how many new 
cancer diagnoses per year are 
there among patients in your 
practice? 
 0 – 50 
 51 – 100 
 101 – 150  
 > 150  
 
 
Do you have standard protocols 
in place for the management of 
relapsed and refractory patients? 
 Yes for more than 75% of diagnoses 
 Yes for 50-74% of diagnoses 
 Yes for <50% of diagnoses 
 
 
Do you have access to a 







What type of paediatric 
palliative care programme do 
you have access to? 
 Inpatient consult service 
 Outpatient consult service 
 Local hospice 
 Other 
 
General experiences in the use of palliative chemotherapy: 
Physicians often differ in their opinions of when to recommend a palliative approach. There are 
clearly many factors that go into a decision to pursue palliative versus curative therapies. Please 
answer the following questions using your general experiences with the use of palliative 
chemotherapy. 
 
I believe that palliative 




Disagree Neutral  Agree Strongly 
Agree 
 
A child has a disease that relapsed 
 
     
A child has a disease for which no 
experimental therapies are 
available 
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I believe that palliative 
chemotherapy should be 
recommended whenever a child 




Disagree Neutral  Agree Strongly 
Agree 
>99%      
>95%      
>90%      
>75%      
>50%      
 
In your experience what 
percentage of children whose 








In your experience, what 
percentage of children whose 








To what degree do you agree or 
disagree that the following 
factor into your 




Disagree Neutral  Agree Strongly 
Agree 
Maximise life expectancy      
Maximise quality of life      
Parental preference      
Standard of care in your practice      
 
 
How often does your individual 
preference regarding the use of 








If there are other factors that 
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chemotherapy, can you share 
them with us? 
 
 





Disagree Neutral  Agree Strongly 
Agree 
Increase length of life      
Improve quality of life      
Maintain quality of life      
Improve patient satisfaction with 
medical care 
     
Improve parental satisfaction with 
medical care 
     
 
When choosing a 
particular palliative 
chemotherapy 
regimen, rank the 















with the disease 
       
Toxicity of the 
chemotherapy regimen 
       
Likely effectiveness of 
the chemotherapy 
regimen 
       
Parental religious or 
cultural beliefs 
regarding disease or 
medical treatments 
       
Perceived preferences 
of the family 
       
Utilisation of medical 
resources 
       
Financial or social 
resources of the patient 
or family 
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Please answer the following questions with regarding to your most recent primary patient 
for whom you prescribed palliative chemotherapy. This patient may or may not have died. 
 






Age of the patient  <1 year 
 1 – 5 years 
 5 – 12 years 
 > 12 years 
 
 
When you first prescribed palliative chemotherapy 
for this patient, how much time had elapsed since 







How long have you been the 
patient’s primary oncologist? 
 0 – 6 months 
 7 – 12 months 
 13 – 24 months 
 > 24 months 
 
 
In this particular case, to what 
degree do you agree or disagree 
that the following factored into 
your decision of which 
palliative chemotherapy 
regimen to prescribe?  
Strongly 
Disagree 
Disagree Neutral  Agree Strongly 
Agree 
Previous experience with the 
disease 
     
Toxicity of the chemotherapy 
regimen 
     
Likely efficacy of the 
chemotherapy regimen 
     
Parental religious or cultural 
beliefs 
     
Perceived preferences of the 
family 
     
Utilisation of medical resources      
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Financial or social resources of 
the patient or family 
     
 
Did the patient receive any palliative chemotherapy 










 Outpatient oral medication 
 Outpatient intravenous medication 
 Inpatient intravenous medication requiring 1-2 day hospitalisation 
 Inpatient intravenous medication requiring 1-2 day hospitalisation 
 Inpatient intravenous medication requiring 1-2 day hospitalisation 
 
 
Did the palliative chemotherapy 
your patient received 
Strongly 
Disagree 
Disagree Neutral  Agree Strongly 
Agree 
Increase length of life      
Improve or enhance quality of life      
Maintain quality of life      
Cause any chemotherapy related 
toxicity that required additional 
sick clinic visits 
     
Cause any chemotherapy related 
toxicity that required additional 
hospitalisations 
     
 
 
Did this patient experience any 
of the following toxicity related 
events as a result of the 
palliative chemotherapy?  
Strongly 
Disagree 
Disagree Neutral  Agree Strongly 
Agree 
Sick visits (clinic)      
Hospitalisations      
ICU level care      
Invasive procedures      
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In cases where the patient has died, please complete the following questions: 
 
Time to death from 
start of palliative 
chemotherapy? 
 < 1 week 
 1 – 4 weeks 
 1 – 3 months 
 4 – 6 months 
 6 – 12 months 
 > 12 months 
 
 
Number of palliative 
chemotherapy 
regimens received 
prior to death? 
 1 regimen 
 2 regimens 
 3 regimens 
 4 or more regimens 
 
 
When did the 
patient receive the 
last chemotherapy? 
 Last day of life 
 Last week of life but not on the last day 
 Last month of life but not in the last week 
 Last three months, but not in the last month 
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APPENDIX 2: Information sheet for questionnaire  
Study title: Use of palliative chemotherapy in South Africa: National survey of 
paediatric oncologists and experience in a single unit. 
 
You are invited to take part in a research study on the use of palliative chemotherapy in South 
Africa. Before you decide to take part it is important that you understand why the research is being 
done and what it would involve for you. Please take time to read the following information 
carefully. Ask questions if anything you read is not clear or if you would like more information. 
Take time to decide whether or not to take  part. 
 
STUDY TEAM AND RESEARCH GOALS 
The study team consists of Ané Büchner, currently a Masters in Palliative Care Student at the 
University of Cape Town, under the supervision of Dr Michelle Meiring (paediatric palliative care 
specialist) and Professor Alan Davidson (head of the Red Cross Children’s hospital paediatric 
oncology/haematology unit). The aim of this questionnaire is to collect data from all the oncology 
units in South Africa about the current use of palliative chemotherapy. In contrast to many first 
world countries, children with a diagnosis of cancer often present to a treating center at a late stage, 
making curative treatment difficult. Palliative chemotherapy can be used to improve quality of life 
and manage symptoms. The use of palliative chemotherapy in South Africa has never been studied. 
This study will be part of Ané’s MPhil thesis and will improve our understanding of the use of 
palliative chemotherapy in South Africa, with the ultimate aim of improving the quality of life of 
our patients.  
 
WHAT WILL PARTICIPATING INVOLVE? 
You are invited to complete a web-based survey that will take 20-30 minutes to complete. If you 
are disconnected or unable to complete the questionnaire in one sitting, the link will remember 
where you left off and you will be able to continue answering questions when reconnected. In the 
survey you will be asked general questions about your oncology treatment center, access to 
palliative care, and your general experience in the use of palliative chemotherapy. You will also 
be asked a series of questions on your most recent patient for whom you prescribed palliative 
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chemotherapy. To answer these questions you may need the folder for this patient when you 
complete the questionnaire. All the questions are tick-boxes and you will not be required to type 
in any answers. 
 
WHY HAVE YOU BEEN INVITED TO TAKE PART? 
We are inviting you to take part because you are on the South African Children’s Cancer Study 
Group (SACCSG) mailing list and you are either a qualified oncologists, haematologist working 
with paediatric oncology patients, or a fellows in paediatric oncology. 
Members of the SACCSG are encouraged to forward the link to this questionnaire to any qualified 
doctors working with them full time in their units who may not yet be part of the SACCSG. 
 
DO YOU HAVE TO TAKE PART? 
Participation in this survey is voluntary. Your work or relationship within the community and 
SACCSG will not be affected by whether you take part in this study. You have the right to refuse 
participation, refuse to answer specific questions, or withdraw at any time without any 
consequences whatsoever. 
 
ARE THERE RISKS OR BENEFITS TO TAKING PART? 
We aim to respect your privacy. Your answers to the questionnaire will not have your name 
attached to them in any publication. We do not anticipate any potential risks to your patients. The 
benefits to the study will be to get a more complete picture of the current use of palliative 
chemotherapy in South Africa, with the aim of increasing knowledge in the field, and in doing so 
improve the quality of life for patients with incurable cancer diagnoses.  
 
WILL TAKING PART BE CONFIDENTIAL? 
Names will not be used in the data collection or analysis process. The patient information gathered 
in the second part of the questionnaire will not be presented in publication in a format that could 
be used to trace the patient. 
 
HOW WILL INFORMATION BE RECORDED, STORED AND PROTECTED? 
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Survey results will be retained on a password-protected external hard drive of the principal 
investigator with hard copies at the University of Cape Town. Survey results will be stored for 
two years from the end of the study. 
 
WHAT WILL HAPPEN TO THE RESULTS OF THE STUDY? 
The results will be published in the principal investigator’s Master’s thesis. The aim will also be 
to publish in peer-reviewed journals as well as present it at relevant conferences. 
 
WHO SHOULD YOU CONTACT WITH ANY QUESTIONS? 
If you should have any questions concerning the survey please contact Ané Büchner 




Ané Büchner (Paediatric oncologist, University of Pretoria; MPhil Palliative Medicine candidate, 
University of Cape Town) 
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APPENDIX 3: Data extraction tool for file review 
Title: Use of palliative chemotherapy in South Africa: National survey of 
paediatric oncologists and experience in a single unit. 
 




Study number  
 
Hospital number  
 
Name and surname   
 
Date of birth dd mm yyyy 
 
Age y m 
 







Closest hospital to home  
 
Travel to oncology unit Hours  
Km  
 
Family structure  Parents both alive and well 
 Single mother 
 Single father 




Number of siblings Age of sibling Gender of sibling 
0   
1   
2   
3   
4   
BCHANE001 
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5   
6   
7   




Source of income  Parents both working 
 Father working 
 Mother working 
 Other family member salary 
  Child support grant 
  Care dependency grant 
  Foster care grant 
  Grant for older persons 
 
Housing  Formal housing 
 Informal settlement 
 
Access to electricity  Yes 
 No 
 
Amenities  Water inside house 
 Water outside the house 
 Flushing toilet inside the house 
 Flushing toilet outside the house 






Stage at diagnosis  
 
Stage when palliative treatment started  No curative treatment offered 
  1st relapse 
  2nd relapse 
  3rd relapse 
  other 
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Time from diagnosis to start of palliative chemotherapy  
 
Was decision to start palliative chemotherapy clearly documented?  Yes 
 No 
 
Was family discussion on palliative chemotherapy done and documented?  Yes 
 No 
 
Aim(s) of palliative chemotherapy  Increased survival time 
 Child’s quality of life 
 Hope 
 Family’s quality of life 
 Opinion of health care professionals 
 Financial considerations 
 Opinion of parents 
 Other: 
 Other: 
 Not documented 
 
Palliative regimen Drug Dose Route 
    
    
    
    
    
 
Reason(s) why palliative 
chemotherapy stopped 
 Side-effects 




 Other:  
 Not documented 
 
Was decision to stop palliative chemotherapy clearly documented?  Yes 
 No 
BCHANE001 
 Page 96 of 99 
 





Cause of death  Progression of disease 
 Treatment related  
 Other: 
 
Place of death  Home 
 Local hospital 
 Oncology unit 
 Other  
 
How long before death was last palliative chemotherapy 
received 
 < 1 week 
 1 week to 1 month 
 1 to 3 months 
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APPENDIX 4: UP HREC approval 
 
BCHANE001 
 Page 99 of 99 
APPENDIX 5: Permission to access data from files at SBAH 
 
